**Table F-2. Comorbid conditions, quality of life, impairment, and ability to return to work**

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Acarturk et al., 2016[44](#_ENREF_44) | G1: EMDR-R-TEP G2: WL | BDI-IIMean (SE at pre-tx; SD at post-tx and followup)G1 Pre-tx:29.85 (9.27)G1 Post-tx: 10.45 (1.73)G1 1 month followup: 12.85 (1.98)G2 Pre-tx: 28.53 (7.99)G2 Post-tx: 26.35 (1.68)G2 1 month followup: 26.13 (1.87)G1 vs G2 pre to posttreatment p<0.001G1 vs G2 pretreatment to followup p<0.001Treatment X Time, F = 0.76, p = 0.368 from posttreatment to followupMean estimated difference, post-tx: -15.90 (95% CI, -20.20 to -11.09), p <0.001Mean estimated difference, 1 month followup: -13.28 (95% CI, -18.73 to -7.82), p <0.001HSCLMean (SE at pre-tx; SD at post-tx and followup)G1 Pre-tx:2.65 (0.50)G1 Post-tx: 1.54 (0.09)G1 1 month followup: 1.73 (0.10)G2 Pre-tx: 2.46 (0.44)G2 Post-tx: 2.34 (0.09)G2 1 month followup: 2.34 (0.09) | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Acarturk et al., 2016[44](#_ENREF_44)(continued) |   | G1 vs G2 pre to posttreatment p<0.001G1 vs G2 pretreatment to followup p<0.001Treatment X Time, F = 1.79, p = 0.186 from posttreatment to followupMean estimated difference, post-tx: -0.89 (95% CI, -1.15 to -0.64), p <0.001Mean estimated difference, 1 month followup: -0.78 (95% CI, -0.96 to -0.43), p <0.001 |   |   |   |
| Acosta et al., 2017[149](#_ENREF_149) | G1: Web CBT plus TAU (Thinking Forward and usual VA primary care services)G2: TAU, usual VA primary care services | Percent of drinking daysTreatment by time effect, NS during treatment period, Estimate: -0.93 (1.12)Treatment by time effect, NS contrasting between in and post-treatment, Estimate: 1.67 (1.84)Percent of heavy drinking daysTreatment by time effect, during treatment period, Estimate: -1.80 (0.79), p<0.05Treatment by time effect, NS contrasting between in and post-treatment, Estimate: 1.89 (1.33)Percent of drug use daysTreatment by time effect, NS during treatment period, Estimate: -0.27 (0.25)Treatment by time effect, NS contrasting between in and post-treatment, Estimate: -0.06 (0.49) | QOL – Physical domainTreatment by time effect, NS during treatment period, Estimate: 0.75 (0.52)Treatment by time effect, NS contrasting between in and post-treatment, Estimate: -0.51 (0.91)QOL – psychological domainTreatment by time effect, NS during treatment period, Estimate: 0.77 (0.58)Treatment by time effect, NS contrasting between in and post-treatment, Estimate: -0.88 (0.94)QOL – social domainTreatment by time effect, NS during treatment period, Estimate: 1.27 (1.02) | NR | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Acosta et al., 2017[149](#_ENREF_149)(continued) |   |   | Treatment by time effect, NS contrasting between in and post-treatment, Estimate: -2.00 (1.72)QOL – environment domainTreatment by time effect, NS during treatment period, Estimate: 0.13 (0.61)Treatment by time effect, NS contrasting between in and post-treatment, Estimate: 0.15 (1.02) |   |   |
| Akuchekian et al., 2004[77](#_ENREF_77) | G1: Topiramate25 to 500 mg/day (sensitive patients started at 12.5mg/day)G2: Placebo | NR | NR | NR | NR |
| Asukai et al., 2010[10](#_ENREF_10) | G1: CBT, exposure-based therapyG2: UC | CES-DAdjusted Means (SE)G1 Pre-tx:39.58 (3.53)G1 Post-tx: 20.30 (3.97)G2 Pre-tx:39.50 (3.52)G2 Pre-tx: 34.81 (3.65)At post: G1 vs. G2= p<0.05(based on t-test) | GHQ-28Adjusted Means (SE)G1 Pre-tx:21.58 (1.89)G1 Post-tx: 10.04 (2.15)G2 Pre-tx:20.50 (1.89)G2 Post-tx: 17.65 (1.97)At post: G1 vs. G2= p<0.05(based on t-test) | NR | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Bartzokis et al., 2005[86](#_ENREF_86) | G1: Risperidone1 to 3 mg/day G2: Placebo | HAM-AUnadjusted Change from baseline (SD)G1: -7.4 (5.7)G2:-2.0 (7.0)G1 vs. G2, p<0.001HAM-DUnadjusted Change from baseline (SD)G1: -3.7 (8.0)G2: -1.4 (8.7)G1 vs. G2, p>0.05 | NR | NR | NR |
| Basoglu et al., 2007[11](#_ENREF_11) | G1: CBT, exposure-based therapyG2: WL | BDIMean (SD)G1 Pre-tx:23.4 (5.9)G1 4 weeks:13.1 (6.2)G1 8 weeks: 13.3 (9.2)G2 Pre-tx:21.9 (3.5)G2 4 weeks: 20.5 (7.4)G2 8 weeks:18.4 (11.0)G1 vs. G2 at Week 4, p<0.01 G1 vs. G2 at Week 8, p<0.007  | NR | Work and Social AdjustmentMean (SD)G1 Pre-tx: 4.1 (0.8)G1 4 weeks: 2.2 (1.4)G1 8 weeks: 1.7 (1.9)G2 Pre-tx: 4.1 (0.9)G2 4 weeks:3.3 (1.4)G2 8 weeks:2.7 (1.6)G1 vs. G2 at Week 4, p<0.01 G1 vs. G2 at Week 8, p<0.007  | NR |
| Batki et al., 2014[165](#_ENREF_165) | G1: Topiramate 25 to 300mgG2: Placebo | Alcohol consumption% Drinking DaysBetween-group analysisWeeks 1 to 12 Avg.G1: 19.5 (34.2)G2: 39.7 (36.5)P p = 0.036, IRR = 0.38, 95% CI 0.15 to-0.94, % diff. = 51Main Effects of treatment, p = 0.063, IRR = 0.430; 95% CI = 0.18 to-1.05 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Batki et al., 2014[165](#_ENREF_165)(continued) |   | %Heavy Drinking DaysBetween-group analysisWeeks 1 to 12 Avg.G1: 11.1 (27.1)G2: 16.8 (26.3)P p = 0.342, IRR = 0.56, 95% CI 0.17 -to 1.87, % diff. = 34Standard Drinks per weekBetween-group analysisWeeks 1 to 12 Avg.G1: 8.7 (19.0)G2: 19.3 (30.5)P p = 0.099, IRR = 0.43, 95% CI 0.16 to-1.17, % diff. = 55Drinks per Drinking DayBetween-group analysisWeeks 1 to 12 Avg.G1: 1.9 (3.3)G2: 4.8 (6.5)P p = 0.057, IRR = 0.45, 95% CI 0.20 to-1.02, % diff. = 60OCDS (Alcohol cravings)Between-group analysisWeeks 1 to 12 Avg.G1: 5.53 (6.55)G2: 11.08 (8.12)P p = 0.025, IRR = -7.02, 95% CI= -13.1 to 0.91, % diff. = 50Main Effects of treatment, F (1,48) = 2.81, p = 0.100 |   |   |   |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Becker et al., 2007[183](#_ENREF_183) | G1: Bupropion100 to 300 mg/dayG2: Placebo | BDIWithin-Group Mean Change (SD) (Baseline-Endpoint)G1: 3.22 (4.77)G2: 3.61 (10.44)Group effect, p<0.05 | NR | NR | NR |
| Blanchard et al., 2003[36](#_ENREF_36) | G1: CBT-mixed G2: Supportive psychotherapyG3: WL | BDIMean (SD)G1 Pre-tx: 24.3 (10.8)G1 Post-tx: 11.6 (12.3)G1 FU: 12.6 (13.5)G2 Pre-tx: 17.8 (13.0)G2 Post-tx: 56.3 (12.2)G2 FU: 17.8 (13.0)G3 Pre-tx: 25.2 (11.9)G3 Post-tx: 24.0 (12.1)Group X Time, Post-TxG1 vs. G2 & G3 (Post-tx) (Group X Time), p<0.001G2 vs G3 (Post-tx) (Group X Time), NSNo changes at 3 mths | NR | GAFMean (SD)G1 Pre-tx: 53.9 (11.4)G1 Post-tx: 75.8 (12.2)G1 FU: 74.7 (12.8)G2 Pre-tx: 56.0 (9.7)G2 Post-tx: 64.3 (13.4)G2 FU: 66.3 (15.1)G3 Pre-tx: 56.0 (13.1)G3 Post-tx: 60.4 (9.6)Group X Time, Post-TxG1 vs. G2, p=0.001G1 vs G3, p=0.001G2 vs & G3, NSNo changes at 3 months | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Blanchard et al., 2003[36](#_ENREF_36) (continued) |   | State-AnxietyMean (SD)G1 Pre-tx: 55.3 (14.1)G1 Post-tx: 38.9 (14.0)G1 FU: 42.6 (15.4)G2 Pre-tx: 56.3 (12.2)G2 Post-tx: 50.7 (12.6)G2 FU: 49.1 (14.5)G3 Pre-tx: 58.5 (10.9)G3 Post-tx: 58.8 (12.3)Group X Time, Post-txG1 vs. G2 & G3, p<0.001G2 vs. G3, significantly greater change for G2Changes at 3 mths, NSTrait-AnxietyMean (SD)G1 Pre-tx: 55.7 (14.0)G1 Post-tx: 41.0 (16.5)G1 FU: 40.6 (15.3)G2 Pre-tx: 56.7 (10.4)G2 Post-tx: 52.4 (12.3)G2 FU: 52.3 (12.6)G3 Pre-tx: 58.9 (10.1)G3 Post-tx: 57.7 (9.9)Group X Time, Post-TxG1 vs. G2 & G3, p<0.001G2 vs. G3, NSChanges at 3 mths |   |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Blanchard et al., 2003[36](#_ENREF_36) (continued) |   | Global Severity Index Mean (SD)G1 Pre-tx: 70.1 (9.3)G1 Post-tx: 57.3 (12.6)G1 FU: 58.4 (14.3)G2 Pre-tx: 73.2 (6.4)G2 Post-tx: 67.6 (9.0)G2 FU: 65.3 (13.1)Group X Time, Post-txG1 vs. G2 & G3, p<0.001G2 vs. G3, significantly greater change for G2 |   |   |   |
| Boden et al., 2012[58](#_ENREF_58) | G1: Seeking Safety and TAUG2: TAU | ASIDrug UseMean (SD)G1 Pre-tx: 0.09 (0.08)G1 Post-tx: 0.06 (0.06)G1 6 mth FU: 0.05 (0.06)G2 Pre-tx: 0.11 (0.08)G2 Post-tx: 0.10 (0.09)G2 6 mth FU: 0.09 (0.09)Between Group Differences at Post-tx, p<0.05Between Group Differences at 6 month FU, p<0.05G1 Within-Group DifferencesPre-tx vs. Post-tx, p<0.05G1 Within-Group DifferencesPre-tx vs. 6mth FU, p<0.05 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Boden et al., 2012[58](#_ENREF_58) (continued) |   | Alcohol UseMean (SD)G1 Pre-tx: 0.29 (0.26)G1 Post-tx: 0.17 (0.19)G1 6 mth FU: 0.14 (0.17)G2 Pre-tx: 0.23 (0.24)G2 Post-tx: 0.15 (0.13)G2 6 mth FU: 0.14 (0.15)Between Group Differences, NSG1 Within-Group DifferencesPre-tx vs. Post-tx, p<0.05G1 Within-Group DifferencesPre-tx vs. 6 month FU, p<0.05G2 Within-Group DifferencesPre-tx vs. Post-tx, p<0.05G2 Within-Group DifferencesPost-tx vs. 6 month FU, p<0.05 |   |   |   |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Bohus et al., 2013[23](#_ENREF_23) | G1: DBT-PTSDG2: TAU-WL | BDI-II (ITT)Mean (SD)G1 Pre-tx: 38.00 (9.75)G1 Post-tx: 26.81(11.45) G1 18 week followup: 28.56 (10.62)G1 24 week followup: 29.47 (12.61)G2 Pre-tx: 39.53(9.13)G2 Post-tx: 40.55 (10.59) G2 18 week followup: 40.18 (11.10)G2 24 week followup: 37.87 (12.62)Hedges’ g between group: 0.70Treatment X Time Interaction: -0.223 (0.089), p<0.0135SCL-90-Revised (ITT)Mean (SD)G1 Pre-tx: 1.90 (0.66)G1 Post-tx: 1.39(0.63) G1 18 week followup: 1.38 (0.63)G1 24 week followup: 1.41 (0.63)G2 Pre-tx: 2.01(0.58)G2 Post-tx: 1.94 (0.64) G2 18 week followup: 1.81 (0.70)G2 24 week followup: 1.73 (0.69)Hedges’ g between group: 0.36Treatment X Time Interaction: -0.002 (0.006), p=0.672 | NR | GAF (ITT)Mean (SD)G1 Pre-tx: 41.50 (4.50)G1 Post-tx: 49.44(8.40) G1 18 week followup: 51.33 (7.88)G1 24 week followup: 51.08 (9.89)G2 Pre-tx: 42.79(7.19)G2 Post-tx: 43.79 (7.51) G2 18 week followup: 42.92 (8.00)G2 24 week followup: 42.92 (8.00)Hedges’ g between group: 1.02Treatment X Time Interaction: 0.503 (0.094), p<0.001 | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Brady et al., 2000[66](#_ENREF_66) | G1: Sertraline25 to 200 mg/dayG2: Placebo | HAM-DMean Change (SEM)G1: -8.6 (1.3)G2: -5.0 (1.2)G1 vs. G2, p=0.04 | Q-LES-Q Mean Change (SEM)G1: 11.7 (2.1)G2: 3.3 (16.7)G1 vs. G2, p=0.004 | CAPS social functioning subscaleMean Change (SEM)G1:-1.2 (0.11)G2: -0.7 (0.11)G1 vs. G2, p=0.001CAPS occupational functioning subscaleMean change(Endpoint – Baseline) (SEM)G1:-0.7 (0.10)G2: -0.4 (0.10)G1 vs. G2, p=0.001 | NR |
| Brady et al., 2005[67](#_ENREF_67) | G1: Sertraline150 mg/dayG2: Placebo | HAM-DANOVANo significant between-group differences (p>0.05) | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Bryant et al., 2003[41](#_ENREF_41) | G1: CBT, exposure based therapy(PE)G2: CBT-Mixed Prolonged Imaginal Exposure plus CRG3: Supportive Control | STAI-StateMean (SD)G1 Pre-tx: 56.80 (11.22)G1 Post-tx: 43.10 (13.52)G1 6 mth FU: 42.85 (14.90)G2 Pre-tx: 54.60 (8.20)G2 Post-tx: 41.45 (14.77)G2 6 mth FU: 43.45 (11.85)G3 Pre-tx: 56.28 (11.12)G3 Post-tx: 51.50 (12.00)G3 6 mth FU: 53.33 (9.70)Post-tx, p<0.01 (main effects)FU, p<0.05 (main effect)BDI Mean (SD)G1 Pre-tx: 21.65 (11.18)G1 Post-tx: 17.45 (12.82)G1 6 mth FU: 16.15 (12.19)G2 Pre-tx: 23.15 (10.05)G2 Post-tx: 13.85 (14.31)G2 6 mth FU: 14.95 (13.99)G3 Pre-tx: 26.56 (11.15)G3 Post-tx: 23.78 (12.10)G3 6 mth FU: 25.33 (12.05)Post-tx, p<0.01 (main effect)FU, p<0.05 (main effect) | NR | Good End State Functioning at Followup (Being below specific cut-off scores for both PTSD and depression)G1: 15.0%G2: 40.0%G3: 0.0%G1 vs. G3, p<0.01G1 vs. G2, p<0.07 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Bryant et al., 2008[42](#_ENREF_42) | G1: CBT, exposure based (Imaginal Exposure)G2: CBT, exposure-based therapy (In vivo exposure)G3: CBT, exposure-based therapy (Imaginal Exposure/In vivo Exposure)G4: CBT-mixed Imaginal Exposure/In vivo Exposure/ cognitive restructuring | STAIMean (SD)G1 Pre-tx: 59.10 (15.08)G1 Post-tx: 50.71 (16.36)G1 6 mth FU: 56.19 (16.03)G2 Pre-tx: 58.25 (15.62)G2 Post-tx:50.36 (18.68)G2 6 mth FU: 51.14 (17.88)G3 Pre-tx: 59.32 (12.75)G3 Post-tx:48.87 (16.74)G3 6 mth FU: 54.84 (15.44)G4 Pre-tx: 56.93 (12.75)G4 Post-tx: 46.46 (17.21)G4 6 mth FU: 46.89 (24.54)Post-tx, NS (main effect)6 month FU, NS (main effect)BDIMean (SD)G1 Pre-tx: 24.03 (10.81)G1 Post-tx: 21.31 (13.23)G1 6 mth FU: 20.58 (12.83)G2 Pre-tx: 25.38 (12.82)G2 Post-tx:19.36 (11.28)G2 6 mth FU: 19.79 (12.43)G3 Pre-tx: 24.23 (11.38)G3 Post-tx: 22.16 (15.44)G3 6 mth FU: 24.81 (14.90) | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Bryant et al., 2008[42](#_ENREF_42) (continued) |   | G4 Pre-tx: 21.79 (10.25)G4 Post-tx:13.96 (12.05)G4 6 mth FU: 13.54 (11.85)Post-tx, NS (main effect)6 month FU, p<0.05 (main effect) |   |   |   |
| Butterfield et al., 2001[82](#_ENREF_82)  | G1: Olanzapine5 to 20mg/dayG2: Placebo | NR | NR | SDSMean (SD)G1 Pre-tx: 19.8 (7.9)G2 Post-tx: 12.1 (7.8)Change: -7.7G2 Pre-tx: 21.6 (7.2)G2 Post-tx: 13.6 (8.7)Change: -8.0G1 vs. G2, no group X time differences found | NR |
| Carey et al., 2012[81](#_ENREF_81) | G1: Olanzapine 5 to 10mgG2: Placebo | MADRSMean (SD)G1 Pre-tx: 15.9 (4)G1 Post-tx 8 week: 10.3 (6.8)G2 Pre-tx: 15.3 (2.9)G2 Post-tx 8 week: 15.3 (9.8)Week 8 G1 vs. G2, p = 0.137, Effect size, r = 0.29 | NR | SDSMean (SD)G1 Pre-tx: 18.3 (7.1)G1 Post-tx 8 week: 10.6 (6.9)G2 Pre-tx: 24.1 (4.2)G2 Post-tx 8 week: 20.6 (7.4)Week 8 G1 vs. G2, p = 0.004, Effect size, r = 0.57 | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Carlson et al., 1998[46](#_ENREF_46)  | G1: EMDRG2: CBT, coping skills therapy (Biofeedback and general relaxation)G3: WL | BDI Mean (SD)G1 Pre-tx: 20.1 (7.5)G1 Post-tx: 6.9 (5.9)G1 3 mth FU: 8.6 (9.4) G1 9 mth FU:6.6 (5.9)G2 Pre-tx: 23.6 (10.8)G2 Post-tx: 15.8 (12.5)G2 3 mth FU: 18.3 (11.7)G2 9 mth FU:22.5 (12.1)G3 Pre-tx: 24.0 (9.9)G3 Post-tx: 23.5 (12.8)Post & 3 mthsGroup X Time, p<0.004G1 vs. G3, p<0.01 (post)G1 vs. G2, NS (3 months)9 month FUp<0.00 (t-test)STAI-State G1 Pre-tx: 47.2 (9.4)G1 Post-tx: 34.9 (9.0)G1 3 mth FU:40.6 (4.9)G2 Pre-tx: 58.2 (12.2)G2 Post-tx: 46.3 (13.3)G2 3 mth FU:47.7G3 Pre-tx: 58.2 (10.5)G3 Post-tx: 51.4 (17.8)Post-tx & 3 mthsGroup X Time, NS9 mo FU: DataNR | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Carlson et al., 1998[46](#_ENREF_46) |   | STAI-Trait Mean (SD)G1 Pre-tx: 54.0 (9.9)G1 Post-tx: 38.6 (9.7)G1 3 mth FU: 41.9 (6.9)G2 Pre-tx: 58.0 (9.1)G2 Post-tx: 50.8 (10.7)G2 3 mth FU: 51.8 (7.4)G3 Pre-tx: 61.7 (10.6)G3 Post-tx: 55.8 (11.2)Group X Time, p<0.06Post-txG1 vs. G3, p<0.001G1 vs G2, p<0.013 month FUG1 vs. G2, p<0.01 |   |   |   |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Chard et al., 2005[2](#_ENREF_2) | G1: CBT, cognitive processing therapyCPT-SAG2: WL  | BDI-IIMean (SD)G1 Pre-tx: 24.43 (10.81)G1 Post-tx: 3.26 (4.75)G2 Pre-tx: 24.52 (11.55)G2 Post-tx: 22.41 (12.57)p<0.001 | NR | NR | NR |
| Church et al., 2013[155](#_ENREF_155) | G1: EFT, Emotional Freedom Techniques (brief exposure therapy combining cognitive and somatic elements, on PTSD and psychological distress symptoms in veterans) G2: WL | SA-45 GSIMean (SE)G1 Pre-tx: 74.79 (1.4)G1 Post-tx: 58.51 (1.9)G2 Pre-tx: 72.39 (1.6)G2 Post-tx: 69.98 (1.4)Treatment X Time Interaction, p <0.0001SA-45 PSTMean (SE)G1 Pre-tx: 72.74 (1.5)G1 Post-tx: 57.61 (1.9)G2 Pre-tx: 72.72 (1.5)G2 Post-tx: 70.42 (1.3)Treatment X Time Interaction, p <0.0001 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Cloitre et al., 2002[37](#_ENREF_37) | G1: CBT, exposure-based therapy(STAIR)G2: WL | BDIMean (SD)G1 Pre-tx:25 (10.6)G1 Post-tx: 8 (7.8)G2 Pre-tx:23 (9.0)G2 Post-tx: 22 (11.4)p<0.01 (interaction)STAI-SMean (SD)G1 Pre-tx:57 (9.6)G1 Post-tx: 36 (8.6)G2 Pre-tx: 53 (15.6)G2 Post-tx: 55 (14.9)p<0.01 (interaction) | NR | SAS-SRMean (SD)G1 Per-tx:2.44(0.29)G1 Post-tx:2.06 (0.40)G2 Pre-tx:2.57 (0.42)G2 Post-tx: 2.47 (0.53)p=0.02 (interaction) | NR |
| Cloitre et al., 2010[148](#_ENREF_148) | G1: CBT-Mixed (STAIR) + PEG2: CBT-Mixed (STAIR) + Support (Skills Training) G3: Support (Skills Training) + PE | STAIMean (SD)G1 Pre-tx:50.4 (9.41)G1 Post-tx:39.2 (9.92)G1 3 mth FU:38.8 (9.90)G1 6 mth FU:37.4 (10.72)G2 Pre-tx: 48.2 (12.45)G2 Post-tx: 42.9 (12.34)G2 3 mth FU: 41.8 (13.53)G2 6 mth FU:42.4 (12.66)G3 Pre-tx: 50.2 (10.85)G3 Post-tx:41.1 (12.13)G3 3 mth FU:51.8 (11.16)G3 6 mth FU: 47.5 (12.66) |   |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Cloitre et al., 2010[148](#_ENREF_148)(continued) |   | p<0.003 (interaction)3 mth FUG1 vs. G3, p<0.0016 mth FUG1 vs. G3, p<0.003BDIMean (SD)G1 Pre-tx: 18.8 (10.01)G1 Post-tx: 8.9 (7.64)G1 3 mth FU: 9.8 (9.96)G1 6 mth FU: 7.9 (10.77)G2 Pre-tx: 21.1 (8.80)G2 Post-tx: 11.9 (8.54)G2 3 mth FU: 12.0 (8.75)G2 6 mth FU: 13.4 (8.84)G3 Pre-tx: 22.1 (10.60)G3 Post-tx: 12.9 (9.41)G3 3 mth FU: 14.2 (10.09)G3 6 mth FU: 13.6 (9.12)No treatment or interaction effects obtained for BDI | NR | NR | NR |
| Coffey et al., 2016[140](#_ENREF_140) | G1: Modified PE+ Motivational enhancement therapy (met-ptsd), G2: PE as described in G1 without MET, relaxation prior to PE therapy.G3: HLS, relaxation prior to PE therapy | BDI-IIMean (95% CI)G1 Pre-tx: 32.40 (29.21, 35.69)G1 Post-tx: 10.78 (7.07, 14.50)G1 3month followup: 14.34 (9.82, 18.87)G1 6month followup: 13.39 (8.49, 18.30)G2 Pre-tx: 29.49 (26.48, 32.49)G2 Post-tx: 7.08 (3.49, 10.66)\* |   |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Coffey et al., 2016[140](#_ENREF_140) (continued) |   | G2 3 month followup: 10.21 (5.90, 14.51)\*G2 6 month: 6.60 (2.16, 11.19)\*G3 Pre-tx: 29.80 (26.61, 32.90)G3 Post-tx: 13.33 (9.89, 16.77)G3 3 month: 16.84 (12.94, 20.73)G3 6 month: 13.59 (8.97, 18.22)\*Denotes significant improvement over HLS at alpha = .05Treatment x time effect, post-tx: X2 = 5.16, p = 0.08Treatment x time effect, followup: X2 = 1.03, p = 0.91Cohen's d as compared with G3:G1 Post-tx: 0.22G2 Post-tx: 0.26G1 3 month followup: 0.18G2 3 month followup: 0.48G1 6 month followup: 0.006G1 6 month followup: 0.46 |   |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Coffey et al., 2016[140](#_ENREF_140)(continued) |   | Alcohol PDA Mean (95% CI)G1 Pre-tx: 48.70 (41.82 to 55.57)G1 3 month followup: 92.46 (85.66 to 99.25)G1 6 month followup: 85.73 (78.94 to 92.52)G2 Pre-tx: 46.13 (39.04 to 52.61)G2 3 month followup: 97.32 (90.76 to 103.87)G2 6 month followup: 94.49 (87.94 to 101.05)G3 Pre-tx: 52.23 (45.53 to 59.03)G3 3 month followup: 97.08 (90.28 to 103.88)G3 6 month followup: 93.58 (86.78 to 100.37)Treatment x time effect, 3-month followup: X2 = 1.51, p = 0.47Treatment x time effect, 6 month followup: X2 = 1.11, p = 0.58Cohen's d as compared with G3:G1 3 month followup: 0.21G2 3 month followup: 0.01G1 6 month followup: 0.36G2 6 month followup: 0.04 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Coffey et al., 2016[140](#_ENREF_140)(continued) |   | Drug PDA Mean (95% CI)G1 Pre-tx: 45.47 (38.50 to 52.43)G1 3month followup: 93.37 (86.49 to 100.26)G1 6month followup: 91.97 (85.08 to 98.85)G2 Pre-tx: 53.44 (46.87 to 60.01)G2 3 month followup: 97.52 (90.87 to 104.16)G2 6 month: 96.94 (90.87 to 104.16)G3 Pre-tx: 59.59 (52.71 to 66.48)G3 3 month: 97.94 (91.06 to 104.83)G3 6 month: 91.70 (84.82 to 98.59)Treatment x time effect, 3-month followup: X2 = 0.92, p = 0.63Treatment x time effect, 6 month followup: X2 = 2.20, p = 0.33Cohen's d as compared with G3:G1 3 month followup: 0.24G2 3 month followup: 0.02G1 6 month followup: 0.21G1 6 month followup: 0.02 |   |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Connor et al., 1999[170](#_ENREF_170)Meltzer-Brody et al., 2000[171](#_ENREF_171) | G1: Fluoxetine10 to 60mg/dayG2: Placebo | NR | NR | SDSWeek 12 difference (Baseline - Endpoint)(95% CI)G1 vs. G2 Difference: 6.2 (1.4 to 11.0), p<0.05CHEF criterion of response Week 12 difference (Baseline - Endpoint)(95% CI)G1 vs. G2 Difference: 0.37 (0.17 to 0.57), p<0.001 | NR |
| Cook et al., 2010[156](#_ENREF_156) | G1: CBT, exposure-based therapyG2: Psychoeducation | BDIMean (SD)G1 Pre-tx: 26.85 (11.82)G1 at 1 mth: 24.16 (13.35)G1 at 3 mths: 24.80 (13.14)G1 at 6 mths: 25.02 (13.30)G2 Pre-tx: 23.51 (11.92)G2 at 1 month: 22.31 (12.76)G2 at 3 mths:23.76 (12.76)G2 at 6 mths: 23.37 (12.34)Interactions, NS | SF-36 Mental Mean (SD)G1 Pre-tx:29.69 (9.08) G1 at 1 mth:32.33 (10.63)G1 at 3 mths: 30.98 (9.33)G1 at 6 mths:32.15 (8.99)G2 Pre-tx:34.52 (12.06) G2 at 1 mth:32.84 (9.75) G2 at 3mths: 34.00 (10.35)G2 at 6 mths: 34.78 (10.87)Interactions, NS |   | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Cook et al., 2010[156](#_ENREF_156) (continued) |   |   | SF-36 Physical ComponentMean (SD)G1 Pre-tx: 37.17 (9.21) G1 1 mth:39.48 (10.19)G1 at 3 mths: 37.72 (9.57)G1 at 6mths: 35.80 (9.64) G2 Pre-tx: 38.53 (9.64) G2 Post-tx:36.84 (10.34)G2 at 3 mths: 35.96 (11.97)G2 at 6 mths: 37.21 (11.23)Interactions, NS |   |   |
| Cottraux, 2008[31](#_ENREF_31) | G1: CBT-mixed (Exposure in imagination or in vivo and cognitive therapy)G2: Supportive Control | HAM-APost-tx (ITT analysis) G1 Mean Change from Baseline (SD): -11 (9)G2 Mean Change from Baseline (SD): -5.7 (8)Group effect, p=0.028Interaction, p=NS52 WeeksG1 Mean Change from Baseline (sd): -10.04 (11.18), G2 Mean Change from Baseline (sd): -8.79 (10.15), Interaction, p=0.73 | Marks' Quality of Life ScaleITT analysis = NRPost-tx (completer analysis)G1 Mean Change from Baseline (SD): -6.66 (8.13)G2 Mean Change from Baseline (SD): -9.60 (7.98)p=0.26 | Fear Questionnaire, Global Phobic Disability Subscale:ITT analysis = NRPost-tx (completer analysis)POST-TREATMENTG1 Mean Change from Baseline (SD): -2.14 (2.75)G2 Mean Change from Baseline (SDI): -2.00 (2.69) p=0.86 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Cottraux, 2008[31](#_ENREF_31)(continued) |   | 104 WeeksG1 Mean Change from Baseline (sd): -12.56 (11.29), p=NRG2 Mean Change from Baseline (sd): -17.00 (7.19), p=NRInteraction, p=0.30Depression, BDI short formITT = NRCompleter Analysis (Post-tx):G1 Mean Change from Baseline (sd): -5.44 (6.15)G2 Mean Change from Baseline (sd): -4.66 (6.95), Interaction, p=0.7052 WEEKSG1 Mean Change from Baseline (sd): -4.33(5.65), G2 Mean Change from Baseline (sd): -4.07 (5.80), Interaction, p=0.89104 WEEKS:G1 Mean Change from Baseline (sd): -5.87 (6.66), p=NRG2 Mean Change from Baseline: -6.22 (5.84), p=NRInteraction, p=0.89 |   |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Cottraux, 2008[31](#_ENREF_31) (continued) |   |   | 52 WeeksG1 Mean Change from Baseline (SD): -9.42 (9.36), p=NRG2 Mean Change from Baseline (SD): -7.64 (9.12), p=NRInteraction, p=0.57104 WeeksG1 Mean Change from Baseline (SD): -10.00 (7.65), p=NRG2 Mean Change from Baseline (SD): -12.66 (8.23), p=NRInteraction, p=0.42 | 52 WeeksG1 Mean Change from Baseline (SD): -2.54 (2.90), p=NRG2 Mean Change from Baseline (SDI): -1.00 (2.48), p=NRInteraction, p=0.11104 WeeksG1 Mean Change from Baseline (SD): -3.52 (2.79), p=NRG2 Mean Change from Baseline (SDI): -2.33 (2.82), p=NRInteraction, p=0.44 |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Davidson et al., 2001[68](#_ENREF_68) | G1: Sertraline50 to 200 mg/dayG2: Placebo | HAM-DChange from Baseline to Endpoint (SD)G1: -7.7 (1.0)G2: -6.3 (1.0)p=0.33 (t-test)HAM-AChange from Baseline to Endpoint (SD)G1: -7.8 (0.8)G2: -6.4 (0.9)p=0.26 (t-test) | NR | NR | NR |
| Davidson et al., 2003[184](#_ENREF_184) | G1: Mirtazapine15 to 45 mg/dayG2: Placebo | HADS-DMean (SD)G1 Pre-tx: 10.2 (6.1)G1 Post-tx: 8.0 (6.0)G2 Pre-tx: 13.5 (4.3)G2 Post-tx: 13.0 (3.7)Treatment effect, p=0.08HADS-AG1 Pre-tx: 11.8 (5.0)G1 Post-tx: 9.0 (5.8)G2 Pre-tx: 15.0 (3.3)G2 Post-tx 13.8 (3.7)Treatment effect, p<0.05 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Davidson et al., 2006[69](#_ENREF_69) | G1: Venlafaxine75 to 300mg/dayG2: Sertraline50 to 200mg/dayG3: Placebo | HAM-D Mean Within-group difference (95% CI)G1: -7.09(-8.13 to -6.05) G2: -6.42 (-7.48 to - 5.37)G3: -5.54 (-6.58 to -4.50)Between group p-values based on pairwise comparisons from the analysis of variance model using baseline adjusted valuesG1 vs. G3: 0.039G2 vs. G3: 0.244G1 vs. G2: 0.379 | Q-LES-Q-SF Mean Within-group difference (95% CI)G1: 11.54 (9.73 to 13.35) G2: 11.17 (9.30 to 13.04)G3: 8.75 (6.94 to 10.56)Between group p-values based on pairwise comparisons from the analysis of covariance model using baseline adjusted valuesG1 vs. G3: 0.033G2 vs. G3: 0.068G1 vs. G2: 0.782  | GAFMean Within-group difference (95% CI)G1: 14.16(12.16 to 16.16) G2: 13.63 (11.57 to 15.70)G3: 11.41 (9.32 to 13.49)Between group p-values based on pairwise comparisons from the analysis of covariance model using baseline adjusted valuesG1 vs. G3: 0.062G2 vs. G3: 0.136G1 vs. G2: 0.720 SDSMean Within-group difference (95% CI)G1: -8.54 (-9.78 to -7.29)G2:-8.17 (-9.43 to -6.90)G3: -6.52 (-7.76 to -5.29)Between group p-values based on pairwise comparisons from the analysis of covariance model using baseline adjusted valuesG1 vs. G3: 0.025G2 vs. G3: 0.068G1 vs. G2: 0.683 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Davidson et al., 2006[73](#_ENREF_73) | G1: Venlafaxine37.5 to 300 mg/dayG2: Placebo |  HAM-DBetween Group Mean Difference-1.4, p=0.007 | Q-LES-Q-SF Between Group Mean Difference3.7, p=0.007 | SDS Between Group Mean Difference-2.0, p=0.03GAFBetween Group Mean Difference3.3, p=0.03 |   |
| Davidson et al., 2007[166](#_ENREF_166) | G1: Tiagabine4 to16mg/dayG2: Placebo | NR | NR | SDSChange from baseline (SD)G1: -5.5 (7.0)G2: -5.9 (7.7)p=0.74 | NR |
| Davis et al., 2008[164](#_ENREF_164) | G1: Divalproex1000 to 3000 mg/dayG2: Placebo | MADRSMean (SD)G1 Pre-tx: 27.3 (8.5)G1 Post-tx:22.2 (10.6)G2 Pre-tx: 28.5 (7.1)G2 Post-tx: 24.0 (10.3)Diff b/t groups, p=NSHAM-AMean (SD)G1 Pre-tx:24.1 (10.1)G1 Post-tx:19.4 (9.1)G2 Pre-tx: 22.8 (8.5)G2 Post-tx::20.1 (10.7)Diff b/t groups, p=NS | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ehlers et al., 2003[5](#_ENREF_5) | G1: CTG2: Self-help booklet based on principles of CBTG3: Repeated assessments | BDI Mean (SD) G1 Pre-tx: 18.8 (6.7)G1 3 mth FU: 7.3 (6.3)G1 9 mth FU: 6.5(7.0)G2 Pre-tx: 22.9 (9.2)G2 3 mth FU: 16.1 (6.6) G2 9 mth FU: 15.2 (6.9)G3 Pre-tx: 22.7 (8.9)G3 3 mth FU: 17.1 (9.6)G3 9 mth FU: 12.0 (10.0) 3 mth FUOverall: p<0.001G1 vs. G2, p<0.001G1 vs. G3, p<0.0019 mth FUOverall: p<0.001G1 vs. G2, p<0.001G1 vs. G3, p=0.02BAIMean (SD) G1 Pre-tx: 21.6 (7.9)G1 3 mth FU: 6.0 (5.8)G1 9 mth FU: 5.8 (4.9) G2 Pre-tx: 22.2 (9.9)G2 3 mth FU: 14.2 (8.9)G2 9 mth FU: 14.0 (8.6)G3 Pre-tx: 24.4 (7.4)G3 3 mth FU: 15.7 (10.4)G3 9 mth FU: 12.6 (8.6) | NR | SDSMean (SD) G1 Pre-tx: 5.9 (2.4)G1 3 mth FU: 2.3 (2.8)G1 9 mth FU: 1.8 (2.5)G2 Pre-tx: 6.3 (2.0)G2 3 mth FU: 4.3 (2.5)G2 9 mth FU: 3.7 (2.2)G3 Pre-tx: 6.1 (1.9)G3 3 mth FU: 4.2 (1.9)G3 9 mth FU: 3.2 (2.7)3 mth FUOverall: p<0.001G1 vs.G2, p=0.001G1 vs. G3, p<0.001 9 mth FUOverall: p=0.003 G1 vs. G2, p=0.001 G1 vs. G3, p= 0.007 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ehlers et al., 2003[5](#_ENREF_5)(continued) |   | 3 mth FUOverall: p<0.001 G1 v.s G2: p<0.001 G1 vs. G3: p<0.0019 mth FUOverall: p<0.001 G1 vs. G2, p<0.001 G1 vs. G3, p<0.001 |   |   |   |
| Ehlers et al., 2005[8](#_ENREF_8) | G1: CBT-mixed Cognitive therapy including restructuring and exposureG2: WL | BDIMean (SD)G1 Pre-tx: 23.7 (9.0)G1 Post-tx: 10.6 (8.6)G1 6 mth FU: 11.2 (9.6)G2 Pre-tx: 23.2 (8.0)G2 Post-tx: 19.3 (7.2)G1 vs. G2, p=0.003G1 Changes, p<0.0005G2 Changes, p=0.025BAIMean (SD)G1 Pre-tx: 24.1 (11.1)G1 Post-tx: 8.2 (10.8)G1 6 mth FU: 7.5 (9.7)G2 Pre-tx: 19.2 (7.2)G2 Post-tx: 21.2 (11.2)G1 vs. G2, p<0.0005G1 Changes, p<0.0005G2 Changes, NS | NR | SDSMean (SD)G1 Pre-tx: 7.6 (1.9)G1 Post-tx: 3.0 (2.6)G1 6 mth FU: 3.0 (2.6)G2 Pre-tx: 6.7 (1.9)G2 Post-tx: 6.3 (1.8)G1 vs. G2, p<0.0005G1 Changes, p<0.0005G2 Changes, NS | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ehlers et al., 2014[9](#_ENREF_9) | G1: Intensive CT (standard CT delivered over a much shorter period)G2: Standard CTG3: Supportive TherapyG4: WL | BDI (ITT)Mean (SD)G1 Pre-tx: 23.93 (9.86)G1 6 weeks: 14.34 (9.30)G1 Post-tx:12.10 (9.97)G1 Followup 1 (27 weeks): 12.03 (11.25)G1 Followup 2 (40 weeks):12.84(12.54)Within-group pre-post effect, d= 1.19G2 Pre-tx: 21.90 (10.77)G2 6 weeks: 13.39 (10.70)G2 Post-tx: 11.07 (11.80)G2 Followup 1 (27 weeks): 10.54 (12.70)G2 Followup 2 (40 weeks): 9.44 (12.18)Within-group pre-post effect, d = 0.96G3 Pre-tx: 26.18 (10.68)G3 6 weeks: 19.79 (12.42)G3 Post-tx: 17.00 (12.82)G3 Followup 1 (27 weeks): 16.29(12.10)G3 Followup 2 (40 weeks): 18.60 (14.05)Within-group pre-post effect, d = 0.78G4 Pre-tx: 23.47 (8.96)G4 6 weeks: 21.26 (8.06)G4 Post-tx: 20.85 (10.02)Within-group pre-post effect, d = 0.28 | Quality of Life Enjoyment an Satisfaction Questionnaire (ITT)Mean (SD)G1 Pre-tx: 36.93 (12.84)G1 6 weeks: 49.54 (17.23)G1 Post-tx:52.67 (20.21)G1 Followup 1 (27 weeks): 58.10 (22.78)G1 Followup 2 (40 weeks):54.57(20.74)Within-group pre-post effect, d= 0.93G2 Pre-tx: 39.36 (21.87)G2 6 weeks: 57.49 (20.82)G2 Post-tx: 62.93 (21.70)G2 Followup 1 (27 weeks): 60.43 (23.31)G2 Followup 2 (40 weeks): 65.11 (22.46)Within-group pre-post effect, d = 1.08G3 Pre-tx: 38.78 (18.40)G3 6 weeks: 44.86 (25.25)G3 Post-tx: 49.22 (24.97)G3 Followup 1 (27 weeks): 49.61(25.67) | SDS (ITT)Mean (SD)G1 Pre-tx: 20.48 (5.55)G1 6 weeks: 10.72 (7.51)G1 Post-tx:9.30 (8.20)G1 Followup 1 (27 weeks): 10.61 (8.80)G1 Followup 2 (40 weeks):9.72(9.22)Within-group pre-post effect, d= 1.60G2 Pre-tx: 21.39 (5.11)G2 6 weeks: 14.02 (9.35)G2 Post-tx: 10.02(9.76)G2 Followup 1 (27 weeks): 8.68 (9.50)G2 Followup 2 (40 weeks): 9.37 (10.07)Within-group pre-post effect, d = 1.50G3 Pre-tx: 19.65 (6.97)G3 6 weeks: 16.60 (7.90)G3 Post-tx: 14.28 (9.09)G3 Followup 1 (27 weeks): 13.67(9.86)G3 Followup 2 (40 weeks): 14.47 (11.35Within-group pre-post effect, d = 0.66G4 Pre-tx: 17.28 (7.74)G4 6 weeks: 17.22 (6.67)G4 Post-tx: 17.20 (6.38)Within-group pre-post effect, d = 0.01 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ehlers et al., 2014[9](#_ENREF_9)(continued) |   | Comparison of Treatment with WaitlistTreatment by time Interactions, F=5.16, df=3, 122.20, p<0.002Between group effect sizesAdjusted Difference (95% CI)G1 vs. G4: 9.04 (4.26 to 13.81), p<0.001, d = 0.97G2 vs. G4:8.81 (4.06 to 13.55), p<0.001, d= 0.95G1 vs. G3: 3.49(-1.30 to 8.28), NS, d=0.37G2 vs G3: 3.26 (-1.50 to 8.05), NS, d = 0.35Interaction between condition and Linear time effects: F=0.79, df=2, 213.98, p > 0.23BAI (ITT)Mean (SD)G1 Pre-tx: 26.23 (13.12)G1 6 weeks: 13.55 (12.16)G1 Post-tx:11.57 (11.94) Followup 1 (27 weeks): 10.37 (11.59)G1 Followup 2 (40 weeks):11.85(13.35)Within-group pre-post effect, d= 1.17G2 Pre-tx: 28.42 (14.17)G2 6 weeks: 13.88(14.01)G2 Post-tx: 9.24 (12.09)G2 Followup 1 (27 weeks): 9.63 (13.71) | G3 Followup 2 (40 weeks): 50.38 (25.53)Within-group pre-post effect, d = 0.48G4 Pre-tx: 45.68 (20.98)G4 6 weeks: 41.74 (15.13)G4 Post-tx: 46.75 (19.00)Within-group pre-post effect, d = 0.05Comparison of Treatment with WaitlistTreatment by time Interactions, F=6.96, df=3, 106.85, p<0.002Between group effect sizesAdjusted Difference (95% CI)G1 vs. G4: -12.43 (-21.28 to -3.58), p<0.01, d = 0.73G2 vs. G4:-20.67 (-29.39 to -11.95), p<0.001, d= 1.21G1 vs. G3: -4.45(-13.17 to 4.28), NS, d=0.26G2 vs G3: -12.69 (-21.33 to -4.04), p<0.01, d = 0.74 | Comparison of Treatment with WaitlistTreatment by time Interactions, F=14.01, df=3, 109.86, p<0.002Between group effect sizesAdjusted Difference (95% CI)G1 vs. G4: 9.96(6.10 to 13.81), p<0.001, d = 1.33G2 vs. G4: 9.82 (5.95 to 13.68), p<0.001, d= 1.30G1 vs. G3: 5.51(1.71 to 9.31), p<0.01, d=0.74G2 vs G3: 5.37 (1.59 to 9.15), p<0.01, d = 0.72Interaction between condition and Linear time effects: F=7.45, df=2, 220.14, p = 0.001 |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ehlers et al., 2014[9](#_ENREF_9)(continued) |   | G2 Followup 2 (40 weeks): 9.00 (12.61)Within-group pre-post effect, d = 1.46G3 Pre-tx: 25.12 (11.31)G3 6 weeks: 17.01 (13.30)G3 Post-tx: 16.35 (14.56)G3 Followup 1 (27 weeks): 15.50(13.74)G3 Followup 2 (40 weeks): 15.99 (16.15)Within-group pre-post effect, d = 0.67G4 Pre-tx: 23.57 (9.12)G4 6 weeks: 23.26 (10.88)G4 Post-tx: 22.13 (10.59)Within-group pre-post effect, d = 0.15Comparison of Treatment with WaitlistTreatment by time Interactions, F=13.57, df=3, 106.85, p<0.002Between group effect sizesAdjusted Difference (95% CI)G1 vs. G4: 11.98 (6.54 to 17.43), p<0.001, d = 1.13G2 vs. G4:15.58 (10.04 to 20.91), p<0.001, d= 1.45G1 vs. G3: 5.37(0.06 to 10.80), p <0.05, d=0.51G2 vs G3: 8.86 (3.46 to 14.27), p<0.01, d = 0.83 | Interaction between condition and Linear time effects: F=3.27, df=2, 231.98, p = 0.04 |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ehlers et al., 2014[9](#_ENREF_9)(continued) |   | Interaction between condition and Linear time effects: F=5.40, df=2, 176.80, p = 0.005 |   |   |   |
| Engel et al., 2015[26](#_ENREF_26) | G1: DESTRESS-PC (Delivery of Self Training and Education for Stressful Situations-Primary Care), a nurse guided online CBT and SIT G2: Optimized UC, usual primary care PTSD treatment augmented with low intensity care management, feedback to the primary care provider, and training of the clinic providers in management of PTSD. | PHQ-8 (Major Depression)Mean (SD)G1 Pre-tx: 13.53 (5.43)G1 Post-tx (6 weeks): 11.00 (6.65)G1 Post-tx (12 weeks): 9.66 (7.04)G1 Post-tx (18 weeks): 10.23 (7.01)G2 Pre-tx: 11.67 (4.65)G2 Post-tx (6 weeks): 10.24 (5.12)G2 Post-tx (12 weeks): 10.40 (6.77)G2 Post-tx (18 weeks): 8.96 (5.62)Treatment by time interaction, F(3, 186)=2.17, p=0.093PHQ-15 (Somatic symptoms)Mean (SD)G1 Pre-tx: 13.25 (5.64)G1 Post-tx (6 weeks): 11.90 (5.63)G1 Post-tx (12 weeks): 11.37 (6.70)G1 Post-tx (18 weeks): 11.38 (6.16) | SF-36Means NRInteraction terms, NS | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Engel et al., 2015[26](#_ENREF_26)(continued) |   | G2 Pre-tx: 13.31 (5.04)G2 Post-tx (6 weeks): 11.86 (5.18)G2 Post-tx (12 weeks): 12.16 (6.80)G2 Post-tx (18 weeks): 10.79 (6.48)Interaction terms, NS |   |   |   |
| Fecteau et al., 1999[38](#_ENREF_38) | G1: CBT-mixed (Coping skills, exposure-therapy, and cognitive restructuring)G2: WL | BAIMean (SD) G1 Pre-tx: 30.6 (7.4)G1 Post-tx: 15.8 (13.8)G2 Pre-tx: 34.8 (15.8)G2 Post-tx: 32.0 (13.3)Group effect, p-value <0.05 Follow up for G1 OnlyBAIG1 Pre-tx: 30.6 (7.4)G1 Post-tx: 15.8 (13.8)G1 3 mth FU: 16.9 (13.8)G1 6 mth FU: 16.8 (11.8)Change at 3 mths, p<0.05 (n = 10)Change at 6 mths, p<0.01 (n = 8)BDIMean (SD)G1 Pre-tx: 26.3 (9.8)G1 Post-tx: 20.1 (17.1)G2 Pre-tx: 27.9 (10.5) G2 Post-tx: 24.7 (8.1) | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Fecteau et al., 1999[38](#_ENREF_38)(continued) |   | Group effect, NSFollow up for G1 OnlyBDIG1 Pre-tx: 26.3 (9.8)G1 Post-tx: 20.1 (17.1)G1 3 mth FU: 19.6 (15.6)G1 6 mth FU: 15.9 (11.0)\*\*Change at 3 mths, NS (n = 10)Change at 6 mths, NS (n = 8) |   |   |   |
| Foa et al., 1999[14](#_ENREF_14)Zoellner et al., 1999[134](#_ENREF_134) | G1: CBT, exposure-based therapy (PE)G2: CBT, coping skills therapy SITG3: CBT-mixed Combined treatment (PE and SIT)G4: WL | BDIMean (SD)G1 Pre-tx: 17.58 (11.29)G1 Post-tx: 5.75 (4.77)G1 3 mth FU: 8.02 (6.77)G1 6 mth FU: 6.85 (5.61) G1 12 mth FU: 6.15 (7.73)G2 Pre-tx: 21.73 (11.02)G2 Post-tx: 10.05 (8.06)G2 3 mth FU: 14.58 (12.16)G2 6 mth FU: 13.54 (12.51)G2 12 mth FU: 11.92 (14.48)G3 Pre-tx: 21.36 (10.51)G3 Post-tx: 10.49 (9.90)G3 3 mth FU: 13.65 (10.53)G3 6 mth FU: 10.00 (9.46)G3 12 mth FU: 11.88 (9.92)G4 Pre-tx: 25.21 (11.20)G4 Post-tx: 22.10 (14.97)Main Effect, p<0.01G1 vs. G4, p<0.001G2 vs. G4, p<0.05G3 vs. G4, p<0.05 | NR | Social Adjustment Scale - GlobalMean (SD)G1 Pre-tx: 3.73 (0.83)G1 Post-tx: 2.45 (0.60)G1 3 mth FU: 2.58 (0.69)G1 6 mth FU: 2.33 (0.84)G1 12 mth FU: 2.69 (0.87)G2 Pre-tx: 3.79 (1.23)G2 Post-tx: 2.68 (1.00)G2 3 mth FU: 3.00 (1.37)G2 6 mth FU: 2.83 (1.10)G2 12 mth FU: 3.00 (1.30)G3 Pre-tx: 4.00 (1.11)G3 Post-tx: 2.95 (1.33)G3 3 mth FU: 3.37 (1.46)G3 6 mth FU: 2.94 (1.55)G3 12 mth FU: 3.13 (2.03)G4 Pre-tx: 3.93 (1.16)G4 Post-tx: 3.73 (1.10)Treatment Effect, p<0.05G1 vs. G4, p<0.01G2 vs. G4, p=0.08G3 vs. G4, p=0.09Active treatments did not differ from one another, p=0.14 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Foa et al., 1999[14](#_ENREF_14)Zoellner et al., 1999[134](#_ENREF_134)(continued) |   | G1 vs. G3, p<0.025G1 vs. G2, p=0.06STAI-StateMean (SD)G1 Pre-tx: 49.95 (13.70)G1 Post-tx: 32.43 (10.93)G1 3 mth FU: 37.16 (11.80)G1 6 mth FU: 34.95 (11.45)G1 12 mth FU: 34.84 (12.43)G2 Pre-tx: 51.50 (13.37)G2 Post-tx: 39.07 (11.55)G2 3 mth FU: 41.26 (14.02)G2 6 mth FU: 43.33 (17.01)G2 12 mth FU: 42.46 (16.98)G3 Pre-tx: 50.66 (15.37)G3 Post-tx: 40.55 (15.41)G3 3 mth FU: 43.74 (15.27)G3 6 mth FU: 41.12 (14.77)G3 12 mth FU: 38.75 (13.29)G4 Pre-tx: 51.44 (12.60)G4 Post-tx: 50.40 (13.80)Main Effect, p<0.01G1 vs. G4, p<0.001G2 vs. G4, p=0.11G3 vs. G4, p=0.14G2 vs. G3, NSG1 vs. G2, p<0.025G1 vs. G3, p<0.01 |   |  |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Foa et al., 2005[12](#_ENREF_12) | G1: CBT, exposure-based therapy(PE)G2: CBT-mixed (PE plus CR) G3: WL | BDIMean (SD)G1 Pre-tx: 26.1 (9.9)G1 Post-tx: 14.6 (13.8)G2 Pre-tx: 23.4 (9.3)G2 Post-tx: 13.8 (12.9)G3 Pre-tx: 23.6 (10.3)G3 Post-tx: 21.0 (10.7) Group X Time interaction, p<0.001G1 vs. G3, p<0.05G2 vs. G3, p<0.05G1 vs. G2, ns | NR | Social Adjustment Scale - WorkMean (SD)G1 Pre-tx: 3.4 (1.2)G1 Post-tx: 2.8 (1.4)G2 Pre-tx: 3.2 (1.2)G2 Post-tx: 2.7 (1.4)G3 Pre-tx: 3.4 (1.5)G3 Post-tx: 3.5 (1.3)Group X Time interaction, p=0.059Social Adjustment Scale-SocialMean (SD)G1 Pre-tx: 4.1 (1.0)G1 Post-tx: 3.5 (1.3)G2 Pre-tx: 4.0 (1.0)G2 Post-tx: 3.3 (1.2)G3 Pre-tx: 4.0 (1.2)G3 Post-tx: 3.8 (1.1)Group X Time interaction, ns | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Fonzo et al., 2017[137](#_ENREF_137)Fonzo et al., 2017[21](#_ENREF_21) | G1: PEG2: WL | BDI-IIMean (SD)G1 Pre-tx: 23.69 (8.68)G1 Post-tx: 9.69 (7.77)G2 Pre-tx: 23.17 (8.60)G2 Post-tx: 17.87 (9.27)Group X Time interaction, p=0.016 | WHO QOL of BREFMean (SD)Physical HealthG1 Pre-tx: 12.46 (2.99)G1 Post-tx: 14.63 (3.29)G2 Pre-tx: 12.43 (3.11)G2 Post-tx: 12.65 (3.19)Group X Time interaction, p=0.039Psychological HealthG1 Pre-tx: 10.04 (2.29)G1 Post-tx: 13.19 (2.59)G2 Pre-tx: 10.83 (2.34)G2 Post-tx: 11.94 (2.52)Group X Time interaction, p=0.033Social RelationshipsG1 Pre-tx: 9.71 (4.06)G1 Post-tx: 11.83 (3.20)G2 Pre-tx: 9.29(3.51)G2 Post-tx: 10.73 (3.20)Group X Time interaction, p=0.35EnvironmentalG1 Pre-tx: 12.30 (3.48)G1 Post-tx: 14.59 (2.42)G2 Pre-tx: 12.79 (3.37)G2 Post-tx: 13.57 (2.99)Group X Time interaction, p=0.22 | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Forbes et al., 2012[4](#_ENREF_4) | G1: CBT, CPTG2: TAU | BDI-IIMean (SD)G1 Pre-tx: 26.33 (11.38)G1 Post-tx:15.91 (11.97)G1 FU: 14.77 (12.86)G2 Pre-tx: 24.78 (11.99)G2 Post-tx: 20.83 (11.83)G2 FU: 19.11 (10.15)Change over timePost-tx, p=0.054FU, p=0.785STAI-TraitMean (SD)G1 Pre-tx: 59.97 (13.52)G1 Post-tx: 44.59 (13.12)G1 FU: 43.59 (11.49)G2 Pre-tx: 50.29 (9.94)G2 Post-tx: 48.31 (12.75)G2 FU: 47.26 (16.17)Change over timePost-tx, p=0.018FU, p=0.917 | Abbreviated Dyadic Adjustment Scale (ADAS)Mean (SD)G1 Pre-tx: 25.84 (6.95)G1 Post-tx:27.41 (7.72)G1 FU: 25.81 (6.80)G2 Pre-tx: 28.73 (5.13)G2 Post-tx:26.15 (6.34)G2 FU: 27.98 (6.98)Change over timePost-tx, p=0.014FU, p=0.025World Health Organization Quality of Life Scale (WHO-QOL)WHOQOL-Physical Mean (SD)G1 Pre-tx: 19.68 (5.23)G1 Post-tx:21.23 (5.00)G1 FU:19.81 (5.38)G2 Pre-tx: 20.73 (4.69)G2 Post-tx:22.20 (4.90)G2 FU:20.39 (4.70) | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Forbes et al., 2012[4](#_ENREF_4)(continued) |   |   | Change over timePost-tx, p=0.911FU, p=0.453WHOQOL-Psychological Mean (SD)G1 Pre-tx: 15.70 (4.34)G1 Post-tx:18.22 (4.59)G1 FU: 18.40 (4.66)G2 Pre-tx: 15.54 (3.56)G2 Post-tx: 16.23 (4.27)G2 FU: 16.35 (4.88)Change over timePost-tx, p=0.093FU, p=0.955WHOQOL-SocialMean (SD)G1 Pre-tx: 7.77 (2.78)G1 Post-tx: 8.43 (3.36)G1 FU: 8.97 (3.12)G2 Pre-tx: 8.46 (2.83)G2 Post-tx: 8.29 (2.20)G2 FU: 8.00 (2.38) |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Forbes et al., 2012[4](#_ENREF_4)(continued) |   |   | Change over timePost-tx, p=0.152FU, p=0.197WHOQOL-EnvironmentalMean (SD)G1 Pre-tx: 27.50 (4.53)G1 Post-tx: 28.73 (3.97)G1 FU: 28.16 (4.29)G2 Pre-tx: 29.07 (4.80)G2 Post-tx:28.40 (4.89)G2 FU: 28.14 (5.51)Change over timePost-tx, p=0.016FU, p=0.738 |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ford et al., 2011[59](#_ENREF_59) | G1: Trauma Affect Regulation: Guide for Education and Therapy (TARGET)G2: PCTG3: WL | BDIMean (SD)G1 Pre-tx:16.0 (10.8)G1 Post-tx:11.6 (10.9)G2 Pre-tx:17.8 (10.2)G2 Post-tx:11.9 (10.1)G3 Pre-tx:17.8 (10.2)G3 Post-tx:11.9 (10.1)Group X Time Effect, p<0.01STAIMean (SD)G1 Pre-tx: 38.1 (13.0)G1 Post-tx: 31.4 (11.3)G2 Pre-tx:41.6 (13.0)G2 Post-tx:37.4 (13.3)G3 Pre-tx:43.0 (10.9)G3 Post-tx:42.6 (12.9)Group X Time Effect, p=0.19 | NR | NR | NR |
| Ford et al., 2011[60](#_ENREF_60) | G1: Trauma Affect Regulation:Guide for Education andTherapy (TARGET),G2: SGT | TSI Dissociation SymptomsMean (SD)G1 Pre-tx: 14.5 (6.5)G1 Post-tx: 14.1 (6.4)G2 Pre-tx: 12.0 (6.0)G2 Post-tx: 9.1 (5.5)Treatment X Time Interaction at post-tx, F= 1.6, NS, d = -0.26TSI Sexual ConcernsMean (SD)G1 Pre-tx: 9.6 (6.0)G1 Post-tx: 8.2 (7.3) | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ford et al., 2011[60](#_ENREF_60)(continued) |   | G2 Pre-tx: 6.1 (5.2)G2 Post-tx: 5.5 (4.7)Treatment X Time Interaction at post-tx, F= 0.5, NS, d = 0.22TSI Sexual Behavior ProblemsMean (SD)G1 Pre-tx: 9.2 (7.0)G1 Post-tx: 7.0 (7.4)G2 Pre-tx: 7.8 (7.4)G2 Post-tx: 6.6 (7.1)Treatment X Time Interaction at post-tx, F= 1.1, NS, d = 0.31TSI Impaired Self-ReferenceMean (SD)G1 Pre-tx: 14.8 (5.6)G1 Post-tx: 11.4 (5.6)G2 Pre-tx: 12.7 (6.2)G2 Post-tx: 11.4 (5.3)Treatment X Time Interaction at post-tx, F= 2.3, NS, d = 0.39TSI Tension Reduction BehaviorsMean (SD)G1 Pre-tx: 9.3 (5.7)G1 Post-tx: 7.3 (5.1)G2 Pre-tx: 7.5 (5.3)G2 Post-tx: 6.6 (5.3)Treatment X Time Interaction at post-tx, F= 2.0, NS, d = 0.42 |   |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Friedman et al., 2007[70](#_ENREF_70) | G1: Sertraline 25 to 200 mg/dayG2: Placebo | HAM-A Change at Endpoint (SE) G1: -4.1 (1.0)G2: -6.1 (1.1)Between Group Differences, NSHAM-D Change at Endpoint (SE) G1: -2.7 (1.1) G2: -4.2 (1.1)Between Group Differences, NS | NR | NR | NR |
| Galovski et al., 2012[6](#_ENREF_6) | G1: Modified CBT. Modifications include potential addition of stressor sessions and variable length of treatment. G2: Delayed treatment symptom monitoring | BDI-II LSM (SE)G1 Pre-tx: 30.06 (1.53)G1 Post-tx: 9.67 (2.06)Difference: -20.2G2 Pre: 32.50 (1.65)G2 Post: 25.51 (2.13)Difference: -7.0(Hedge's g = .92)G1 vs. G2: -13.2, p < .001 | QOLI LSM (SE)G1 Pre-tx LSM=1.18 (4.65)G1 Post-tx: 21.87 (5.69)Point Improvement: 20.7, p G2 Pre-tx: -.17 (4.81)G2 Post-tx: 3.05 (5.89)Point Improvement: 3.2(Hedge's g = .47)G1 vs. G2: -17.4, p <0.025 | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Galovski et al., 2012[6](#_ENREF_6)(continued) |   |   | SF-36 social functioning G1 Pre-tx: 42.87 (4.06)G1 Post-tx: 73.87 (4.56)G2 Pre-tx: 37.45 (4.29)G2 Post-tx: 39.88 (4.69)(Hedge's g = .95)G1 vs. G2: p < .001SF-36 emotional well-being G1 Pre-tx: 41.29 (2.77)G1 Post-tx: 66.51 (3.62)G2 Pre-tx: 40.89 (2.91)G2 Post-tx: 42.43 (3.83)(Hedge's g = 1.04)G1 vs. G2: p < .001SF-36 general health G1 Pre-tx: 50.43 (3.38)G1 Post-tx: 64.63 (3.48)G2 Pre-tx: 50.35 (3.56)G2 Post-tx: 50.53 (3.66)(Hedge's g = .81)G1 vs. G2: p <.001 |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Gamito et al., 2010[141](#_ENREF_141) | G1: Virtual reality exposure therapy "VRET"G2: CBT, exposure-based therapy (Imaginal exposure)G3: WL | BDIMean (SD)G1 Pre-tx: 24.25 (9.46) G1 Post-tx.: 14.25 (7.67)p=0.003SCL-90-R (Psychopathology)DepressionG1 Change, p=0.011SomatizationG1 Change, p<0.01AnxietyG1 Change, p<0.05 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Gersons et al., 2000[51](#_ENREF_51)  | G1: Eclectic psychotherapy (Brief Eclectic Psychotherapy)G2: WL | Symptom Checklist-90-Phobic Anxiety Subscale Mean (SD)G1 Pre-tx: 21.1 (7.3)G1 Post-tx: 13.4 (5.6)G1 3 mth FU: 13.8 (4.6) G2 Pre-tx: 22.1 (11.0)G2 Post-tx:17.8 (7.4)G2 3 mth FU: 21.1 (7.6) Post-tx G1 vs. G2, p<0.013-mth FU G1 vs. G2, p<0.05Symptom Checklist-90-Anxiety SubscaleMean (SD)G1 Pre-tx: 10.1 (3.1)G1 Post-tx: 7.7 (1.6)G1 3 mth FU: 7.6 (0.9)G2 Pre-tx: 14.4 (4.7)G2 Post-tx: 9.8 (3.7)G2 3 mth FU: 9.8 (3.7)Post-tx G1 vs. G2, p<0.013 mth FU G1 vs. G2, p<0.05Symptom Checklist-90-Depression SubscaleMean (SD)G1 Pre-tx: 35.1 (14.6)G1 Post-tx: 21.0 (7.4)G1 3 mth FU: 21.6 (8.5) | NR | NR | Proportions by Treatment (%, p values)Resumption of Polic workPre-txG1: 18%G2: 25%NSPost-txG1: 77% G2: 70%NS3-month FollowupG1: 86%G2: 60%p<0.05 |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Gersons et al., 2000[51](#_ENREF_51)(continued) |   | G2 Pre-tx: 34.9 (13.0)G2 Post-tx: 28.5 (9.6)G2 3 mth FU: 30.5 (10.5)Post-tx G1 vs. G2, p<0.013 mth FU G1 vs. G2, p<0.05 |   |   |   |
| Haller et al., 2016[145](#_ENREF_145) | G1: Group ICBT for depression and SUD plus CPT-M (trauma-focused CPT modified to include substance use prevention) (individual)G2: Group ICBT for depression and SUD plus ICBT for depression and SUD (individual) | PDAMean (SD)G1 Pre-tx: 0.84 (0.26)G1 Post-tx: 0.81(0.28)G1 Post-tx (1 year followup): 0.73 (0.32)G2 Pre-tx: 0.81 (0.30)G2 Post-tx: 0.79(0.29)G1 Post-tx (1 year followup): 0.72 (0.40) | NR | NR | NR |
| Hamner et al., 2003[83](#_ENREF_83) | G1: Risperidone1 to 6 mg/dayG2: Placebo | NR | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Harned et al., 2014[144](#_ENREF_144) | G1: DBT plus DBT PE G2: DBT | HRSDMean (SD)G1 Pre-tx: 22.9 (5.7)G1 Post-tx: 11.8 (8.0) G1 3 month followup: 12.5 (8.2)G2 Pre-tx: 25.6 (6.2)G2 Post-tx: 15.5 (6.5) G2 3 month followup: 16.8 (3.4)Between Group Effect size, Post: 0.5, followup: 0.6Treatment X time Interaction, F = 0.0 (1, 28), NSHRSAMean (SD)G1 Pre-tx: 25.8 (9.0)G1 Post-tx: 14.2 (10.8) G1 3 month followup: 15.0 (10.6)G2 Pre-tx: 27.6 (10.9)G2 Post-tx: 17.8 (8.6) G2 3 month followup: 16.3 (7.0)Between Group Effect size, Post: 0.3, followup: 0.1Treatment X time Interaction, F = 0.6 (1, 22), NS | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Harned et al., 2014[144](#_ENREF_144)(continued) |   | GISMean (SD)G1 Pre-tx: 2.6 (0.6)G1 Post-tx: 1.1 (0.7) G1 3 month followup: 1.4 (0.9)G2 Pre-tx: 2.2 (0.7)G2 Post-tx: 1.2 (0.5) G2 3 month followup: 1.7 (0.8)Between Group Effect size, Post: 0.2, Followup: 0.2Treatment X time Interaction, F = 0.6 (1, 16), NS |   |   |   |
| Hien et al., 2004[57](#_ENREF_57)  | G1: Seeking SafetyG2: Relapse prevention condition (only substance abuse)G3: UC (Non-randomized Standard community Care) | NR | NR | NR | NR |
| Hien et al., 2009[157](#_ENREF_157)Hien et al., 2012[158](#_ENREF_158) | G1: Seeking SafetyG2: Psychoeducation | NR | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Hinton et al., 2005[34](#_ENREF_34) | G1: CBT-mixed (Information on PTSD and Panic Disorder, relaxation techniques, culturally appropriate visualization, cognitive restructuring, exposure to anxiety-related sensations and trauma related memories, emotional-processing protocol, and cognitive flexibility)G2: WL | Anxiety Sensitivity Index (ASI)Mean (SD)G1 Pre-tx: 3.08 (0.61)G1 2nd Assessment: 1.65 (0.45)G1 3rd Assessment: 1.86 (1.98)G1 FU Assessment: 1.98 (0.40)G2 Pre-tx: 3.27 (0.53)G2 2nd Assessment: 3.19 (0.36)G2 3rd Assessment 1.84 (0.42)G2 FU Assessment: 1.91 (0.49)Group Diffferences at 2nd Assessment, p<0.001Group Differences at 1st, 3rd, & 4th assessments, NSAverage of the Symptom Checklist-90-R's Anxiety and Depression subscale (SCL)Mean (SD)G1 Pre-tx: 2.92 (0.61)G1 2nd Assessment: 1.72 (0.43)G1 3rd Assessment: 1.77 (0.30)G1 FU Assessment: 2.02 (0.78) | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Hinton et al., 2005[34](#_ENREF_34)(continued) |   | G2 Pre-tx: 3.02 (0.51)G2 2nd Assessment: 2.94 (0.45)G2 3rd Assessment: 2.03 (0.41)G2 FU Assessment: 1.96 (0.89) Group Diffferences at 2nd Assessment, p<0.001Group Differences at 1st, 3rd, & 4th assessments, NS |   |   |   |
| Hinton et al., 2009[151](#_ENREF_151) | G1: CBT-Mixed (Information on PTSD and Panic Disorder, muscle relaxation, guided imagery, mindfulness training, yoga-like stretching, cognitive restructuring, various exercises to teach emotional distancing and switching, and interoceptive exposure)G2: WL | NR | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Hinton et al., 2011[152](#_ENREF_152) | G1; CBT-mixed Culturally Adapted CBT (coping skills, cognitive "modification", mentions exposure) G2: Applied Muscle Relaxation  | SCL Anxiety ScaleMean (SD)G1 Pre-tx: 2.5 (0.5)G1 Post-tx: 1.5 (0.7)G1 FU: 1.4 (0.6)G2 Pre-tx: 2.6 (0.6)G2 Post-tx: 2.2 (0.7)G2 FU: 2.1 (0.8)Post-txG1 vs. G2, p<0.05 (t-test)FUG1 vs. G2, p<0.05 (t-test) | NR | NR | NR |
| Hogberg et al., 2007[48](#_ENREF_48) | G1; EMDRG2: WL | BAIMean (SD)Pre-txG1 Pre-tx: 16.7 (10.0)G1 Post-tx: 9.5 (14.0)G2 Pre-tx: 13.1 (9.3)G2 Post-tx: 11.4 (4.9) Within group changeG1: p<0.05G2: NSBetween group change, NSHAM-AMean (SD)G1 Pre-tx: 16.0 (6.5)G1 Post-tx: 9.8 (7.2)G2 Pre-tx: 18.2 (6.6) G2 Post-tx: 16.1 (5.1) |   | GAFMean (SD)G1 Pre-tx: 64.0 (3.6)G1 Post-tx: 78.9 (12.5)G2 Pre-tx: 64.9 (3.9) G2 Post-tx: 66.8 (6.0)Within group changeG1: p<0.05G2: NSBetween group change, p<0.05SDIMean (SD)G1 Pre-tx: 4.5 (2.3)G1 Post-tx: 4.2 (3.3)G2 Pre-tx: 5.9 (4.5) G2 Post-tx: 5.4 (3.4) | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Hogberg et al., 2007[48](#_ENREF_48)(continued) |   | Within group changeG1: p<0.05G2: NSBetween group change, NSHAM-DMean (SD)G1 Pre-tx: 29.5 (3.5)G1 Post-tx: 26.8 (5.0)G2 Pre-tx: 30.0 (3.4)G2 Post-tx: 31.3 (4.5)Within group changeG1: NS G2: NSBetween group change, p<0.05 |   | Within group changeG1: NSG2: NSBetween group change, NS |   |
| Hollifield et al., 2007[32](#_ENREF_32) | G1: AcupunctureG2: CBT-mixed (Cognitive restructuring, behavior activation, and coping skills) G3: WL | Depression (HSCL-25)Mean (SD)G1 Pre-tx: 2.50 (0.70)G1 Post-tx: 1.89 (0.76)G1 3 mth FU: 1.88 (0.75)G2 Pre-tx: 2.63 (0.53)G2 Post-tx: 2.00 (0.63)G2 3 mth FU: 1.91 (0.69)G3 Pre-tx: 2.61 (0.65)G3 Post-tx: 2.53 (0.67)G3 3 mth FU: 2.53 (0.67)RMANOVAG1 vs. G2, p=0.77 G1 vs. G3, p<0.01G2 vs. G3, p<0.01 | NR | SDIMean (SD)G1 Pre-tx: 3.78 (0.83)G1 Post-tx: 2.98 (1.26)G1 3 mth FU: 2.79 (1.32)G2 Pre-tx: 4.09 (0.81)G2 Post-tx: 3.30 (1.22)G2 3 mth FU: 3.00 (1.29)G3 Pre-tx: 4.00 (1.02)G3 Post-tx: 3.96 (1.04)G3 3 mth FU: 3.96 (1.04)G2 vs. G3, p<0.01 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Hollifield et al., 2007[32](#_ENREF_32)(continued) |   | Anxiety (HSCL-25)Mean (SD)G1 Pre-tx: 2.45 (0.57)G1 Post-tx: 1.67 (0.72)G1 3mth FU: 1.66 (0.56)G2 Pre-tx: 2.40 (0.42)G2 Post-tx: 1.78 (0.54)G2 3 mth FU: 1.81 (0.61)G3 Pre-tx: 2.26 (0.67)G3 Post-tx: 2.14 (0.61)G3 3 mth FU: 2.14 (0.61)RMANOVAG1 vs. G2, p=0.30 G1 vs. G3, p<0.01G2 vs. G3, p<0.01 |   | RMANOVAG1 vs. G2, p=0.83 G1 vs. G3, p<0.01 |   |
| Ivarsson et al., 2014[24](#_ENREF_24) | G1: Internet based CBTG2: Delayed treatment attention control | BDI-II (ITT)Mean (SD)G1 Pre-tx: 26.61 (11.42)G1 Post-tx: 16.11 (10.49)G2 Pre-tx: 26.35 (10.88)G2 Post-tx: 22.19 (10.50)Treatment by time interaction = -6.1 (95% CI, -10.7 to -1.6), t (58) = 2.7, p=0.009, d = 0.55 (95% CI, 0.00 to 1.09), favoring treatmentBAI (ITT)Mean (SD)G1 Pre-tx: 23.03 (10.27)G1 Post-tx: 13.57 (8.15)G1 Followup 1 year: 11.95 (9.33) | QOLI (ITT)Mean (SD)G1 Pre-tx: 0.14 (1.71)G1 Post-tx: 1.15 (1.60)G2 Pre-tx: 0.59 (1.65)G2 Post-tx: 0.62 (1.93)Treatment by time interaction = 0.89 (95% CI, 0.26 to 1.51), t (55) = 2.9, P =0.006, d = 0.53 (95% CI, -0.02 to 1.06), favoring treatment | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ivarsson et al., 2014[24](#_ENREF_24)(continued) |   | G2 Pre-tx: 22.61 (10.51)G2 Post-tx: 20.08 (10.26)Treatment by time interaction = -6.2 (95% CI, -10.3 to -2.1), t (55) = 3.0, P =0.004, d = 0.60 (95% CI, 0.04 to 1.13), favoring treatment |   |   |   |
| Johnson et al., 2011[29](#_ENREF_29) | G1: CBT-mixed(Psychoeducation and CBT restructuring)G2: UC | BDIMean (SD)G1 Pre-tx: 24.17 (9.10)G1 Post-tx: 10.68 (8.80) G1 3 mth FU: 11.61 (10.69)G1 6 mth FU: 8.16 (8.62)G2 Pre-tx: 21.89 (11.54) G2 Post-tx: 18.53 (12.12) G2 3 mth FU: 15.73 (10.90) G2 6 mth FU: 12.85 (11.87) Time effect, p<0.0001Treatment effect, p<0.01 |   | NR | NR |
| Kearney et al., 2013[159](#_ENREF_159) | G1: MBSR+TAUG2: TAU (VHA health system) | PHQ-9 Mean (SD)G1 Pre-tx: 15.92 (6)G1 Post-tx: 12 (6)G1 4 month followup: 12.39 (6)G2 Pre-tx: 16.55 (5)G2 Post-tx: 15.45 (5)G2 4 Month: 15.61 (6)Post-tx, Between group:d = -.62 (95%, CI, -1.24 to 0)4 months, between group: d = -0.55 (95% CI, -1.18 to .08) | SF-8-MCS Mean (SD)G1 Pre-tx: 30.87 (9)G1 Post-tx: 38.27 (10)G1 4 month followup: 37.46 (10)G2 Pre-tx: 30.41 (8)G2 Post-tx: 31.4 (10)G2 4 Month: 62.17 (7)Post-tx, Between group: d = 0.69 (95% CI, 0.07 to 1.32)4 months, Between group = d = .57 (95% CI, -.06 to 1.2) |   | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Kearney et al., 2013[159](#_ENREF_159)(continued) |   | BADS Mean (SD)G1 Pre-tx: 65.38 (20)Posttx Mindfulness: 75.33 (26)4 month Mindfulness: 76.39 (25)Pretx TAU: 65.71 (21)Posttx TAU: 64.21 (15)4 Month TAU: 65.68 (19)Post-tx, Between group: d = 0.52 (95% CI, -.11 to 1.15)4 months, Between group: d = 0.47 (95% CI, -0.15 to 1.09) | Clinically meaningful change (>=10 points) at PostTx:Mindfulness: 12 (57.1%)TAU: 5 (25%)Clinically meaningful change (>=10 points) at 4months:Mindfulness: 8 (36.4%)TAU: 1 (25.6%)SF-8-PCS G1 Pre-tx: 43.43 (10)G2 Post-tx: 41.42 (10)G1 4 month followup: 43.53 (10)G2 Pre-tx: 32.02 (10)G2 Post-tx: 37.29 (11)G2 4 Month followup: 36.60 (9)Post-tx, Between group: d = 0.39 (95% CI, -0.22 to 1) 4 months, Between group: d = 0.73 (95% CI, 0.09 to 1.31 |   |   |
| Krakow et al., 2001[52](#_ENREF_52) | G1: IRT G2: WL | NR | SF-36: no significant changes for either group (results not provided) | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Krystal et al., 2011 [85](#_ENREF_85) | G1; Risperidone1 to 4 mg/dayG2: Placebo | HAMAMean Difference (95% CI) 1.16 (-0.18 to 2.51)p=0.9MADRSMean Difference (95% CI) 1.19 (-.029 to 2.68)p=0.09PANNSSMean Difference (95% CI)-0.21 (-2.37 to 1.96) p=0.85 | BLSIMean Difference (95% CI) -0.32 (-4.04 to 3.40)p=0.87SF-36V PCSMean Difference (95% CI) -1.13 (-2.58 to 0.32)p=0.13SF-36V MCSMean Difference (95% CI) -0.26 (-2.13 to 1.61)p=0.79 | NR | NR |
| Kubany et al., 2003[35](#_ENREF_35) | G1: CBT, cognitive restructuringG2: WL | BDIG1 Mean Change from Baseline (95% CI): 70.8p<.05G2 Mean Change from Baseline (95% CI): 67.5 (pretherapy 1); 64.5 (pretherapy 2)p<.05 | NR | NR | NR |
| Kubany et al., 2004[28](#_ENREF_28) | G1: CBT-Mixed (Cognitive Trauma Therapy-Battered Women)G2: WL | BDI (ITT Sample)Mean (SD)G1 Pre-tx: 26.9 (10.1)G1 Post-tx: 12.0 (14.2)G2 Pre-tx: 27.4 (11.0)G2 Post-tx: 28.7 (10.5)Between group significance, NR | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Langkaas et al., 2017[142](#_ENREF_142) | G1: PE G2: IRT  | BDI-IIMean (SD)G1 Pre-tx: 25.6 (7.41)G1 Post-tx: 13.0 (10.90)G1 3 mth FU: 16.8 (9.68)G2 Pre-tx: 23.6 (7.49)G2 Post-tx: 16.4 (11.31)G2 12 mth FU: 18.0 (12.10)Treatment X Time Interaction, NSSCL-90-R GSIMean (SD)G1 Pre-tx: 1.94 (0.50)G1 Post-tx: 0.99 (0.77)G1 3 mth FU: 1.21 (0.72)G2 Pre-tx: 1.77 (0.52)G2 Post-tx: 1.18 (0.85)G2 12 mth FU: 1.33 (0.81)Treatment X Time Interaction, NS | QOL-PsychologicalMean (SD)G1 Pre-tx: 2.13 (0.52)G1 Post-tx: 3.20 (0.78)G1 3 mth FU: 2.97 (0.77)G2 Pre-tx: 2.34 (0.64)G2 Post-tx: 2.91 (0.89)G2 12 mth FU: 2.76 (0.98)Treatment X Time Interaction, p = 0.05QOL-SocialMean (SD)G1 Pre-tx: 2.71 (0.72)G1 Post-tx: 3.28 (0.76)G1 3 mth FU: 3.15 (0.81)G2 Pre-tx: 2.82 (0.73)G2 Post-tx: 3.25 (0.75)G2 12 mth FU: 3.05 (0.83)Treatment X Time Interaction, NS | NR | NR |
| Li et al., 2017[172](#_ENREF_172) | G1; Sertraline 135 mg G2: Placebo | NR | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Lindauer et al., 2005[50](#_ENREF_50) | G1: Eclectic psychotherapyBrief Eclectic Psychotherapy G2: WL | HADS-Depressive SubscoreMean (SD)G1 Pre-tx: 11.8 (4.3)G1 Post-tx: 8.0 (6.7)G2 Pre-tx: 9.0 (3.5)G2 Post-tx: 9.1 (5.7)G1 vs. G2, p>0.05 HADS-Anxiety SubscoreMean (SD)G1 Pre-tx: 13.1 (3.2)G1 Post-tx: 8.1 (4.8)G2 Pre-tx: 11.3 (3.3)G2 Post-tx: 12.0 (4.7)G1 vs. G2, p<0.05 | NR | NR | Patients on Sick Leave (%) G1 Pre-tx: 66.7%G1 Post-tx: 33.3%G2 Pre-tx: 50%G2 Post-tx: 50%G1 vs. G2, NS |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Litz et al., 2007[33](#_ENREF_33) | G1: CBT-mixed(Stress management skills, in vivo exposure, and relapse prevention)G2: Internet-delivered supportive counseling | BAIG1 Pre-tx: 18.70 (10.60)G1 Post-tx: 8.43 (5.93)G1 3mth FU: 6.11 (5.69)G1 6 mth FU: 6.38 (5.21)G2 Pre-tx: 20.92 (15.00)G2 Post-tx: 12.59 (13.45)G2 3 mth FU: 9.92 (8.19)G2 6 mth FU: 14.43 (9.96)ITT AnalysisPost-txTime effect, p<0.001Completer Analysis3 mth FUG1 vs. G2, NS6 mth FUG1 vs. G2, p =0.06BDIG1 Pre-tx: 18.87 (9.52)G1 Post-tx: 12.14 (9.56)G1 3 mth FU: 12.51 (6.53)G1 6 mth FU: 8.50 (7.54)G2 Pre-tx: 24.43 (12.08)G2 Post-tx: 17.47 (11.19)G2 3 mth FU: 13.23 (9.08)G2 6 mth FU: 16.84 (8.66) | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Litz et al., 2007[33](#_ENREF_33)(continued) |   | ITT Analysis Post-txTime effect, p<0.001Completer Analysis3 mth FUG1 vs. G2, NS6 mth FUG1 vs. G2, p<0.05 |   |   |   |
| Maguen et al., 2017[25](#_ENREF_25) | G1: CBT, Impact of Killing (IOK) G2: WL | BSIMean (SD)G1 Pre-tx: 59.6 (39.8)G1 Post-tx: 41.9 (24.9)Mean change: -17.73 (-32.87 to 2.6), t-test p = 0.0248G2 Pre-tx: 58.7 (30.9)G2 Post-tx: 63.2 (34.6)Mean change: 4.53 (-6.65 to -15.71), t-test p = 0.3991Between-group difference: -21.92 (-37.27 to -6.57) t-test p=, 0.16 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Markowitz et al., 2015[132](#_ENREF_132)Markowitz et al., 2016[261](#_ENREF_261) | G1: PE G2: IPTG3: RT | HAM-DMean (SD)G1 Pre-tx: 20.2 (6.7)G1 Post-tx: 12.3 (8.8)Change at Post-tx: 7.3, Effect size: 1.07G2 Pre-tx: 18.3 (6.5)G2 Post-tx: 13.8 (8.8)Change at Post-tx: 4.2, Effect size: 0.62G3 Pre-tx: 21.0 (7.1)G3 Post-tx: 14.8 (9.1)Change at Post-tx: 7.0, Effect size: 1.03Treatment X Time Interaction at post-tx, X2= 0.128, p = 0.880G1 vs. G3 Difference: -4.42, p = 0.034, Effect Size: -0.65G2 vs. G3 Difference: -0.98, p = 0.642, Effect Size: -0.14G2 vs. G1 Difference: 3.44, p = 0.065, Effect Size: 0.51 | Quality of Life Enjoyment and SatisfactionMean (SD)G1 Pre-tx: 43.5 (14.7)G1 Post-tx: 63.5 (19.2)Change at Post-tx: -17.9, Effect size: -1.33G2 Pre-tx: 43.9 (15.0)G2 Post-tx: 54.6 (18.2)Change at Post-tx: -11.3, Effect size: -0.84G3 Pre-tx: 43.1 (8.7)G3 Post-tx: 46.1 (19.2)Change at Post-tx: -0.8, Effect size: -0.06Treatment X Time Interaction at post-tx, X2= 3.561, p = 0.037G1 vs. G3 Difference: 17.83, p < 0.001, Effect Size: 1.33 | Social Adjustment ScaleMean (SD)G1 Pre-tx: 2.7 (0.6)G1 Post-tx: 2.1 (0.5)Change at Post-tx: 0.4, Effect size: 0.81G2 Pre-tx: 2.7 (0.6)G2 Post-tx: 2.2 (0.5)Change at Post-tx: 0.5, Effect size: 0.93G3 Pre-tx: 2.8 (0.4)G3 Post-tx: 2.7 (0.6)Change at Post-tx: 0.1, Effect size: 0.16Treatment X Time Interaction at post-tx, X2= 3.875, p = 0.022G1 vs. G3 Difference: -0.57, p < 0.001, Effect Size: -1.05G2 vs. G3 Difference: -0.46, p = 0.001, Effect Size: -0.83G2 vs. G1 Difference: 0.12, p = 0.409, Effect Size: 0.21 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Markowitz et al., 2015[132](#_ENREF_132)Markowitz et al., 2016[261](#_ENREF_261)(continued) |   |   | G2 vs. G3 Difference: -10.13, p = 0.017, Effect Size: 0.75G2 vs. G1 Difference: -7.69, p = 0.061, Effect Size: -0.57 | Inventory of Interpersonal ProblemsMean (SD)G1 Pre-tx: 1.7 (0.6)G1 Post-tx: 1.1 (0.6)Change at Post-tx: 0.7, Effect size: 1.26G2 Pre-tx: 1.6 (0.6)G2 Post-tx: 1.0 (0.7)Change at Post-tx: 0.5, Effect size: 0.95G3 Pre-tx: 1.5 (0.4)G3 Post-tx: 1.5 (0.6)Change at Post-tx: -0.1, Effect size: -0.19Treatment X Time Interaction at post-tx, X2= 3.875, p = 0.022G1 vs. G3 Difference: -0.57, p < 0.001, Effect Size: -1.05G2 vs. G3 Difference: -0.46, p = 0.001, Effect Size: -0.83G2 vs. G1 Difference: 0.12, p = 0.409, Effect Size: 0.21 |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Marks et al., 1998[122](#_ENREF_122)Lovell et al., 2001[123](#_ENREF_123) | G1: CBT, exposure-based therapy(PE)G2: CBT, cognitive restructuringG3: CBT-mixed Exposure (Combined with Cognitive Restructuring)G4: Relaxation | BDI (11 weeks)Mean Change Score (95% CI)G1: 13 (8 to 18)G2: 17 (11 to 22)G3: 18 (13 to 23)G4: 7 (3 to 11)Additional results presented in graphsBDIMean change in G1 + G2 + G3 vs. G4Post, p=0.0041 mth FU, p=0.08 | NR | Work/Social Adjustment (Self Report) (Completer data)Mean (SD)G1 Pre-tx: 21.5 (8.9)G1 Post-tx:11.8 (12.3)G1 1 mth FU: 9.5 (12.1)G1 3 mth FU: 5.2 (8.3)G1 6 mth FU: 4.1 (7.8)G2 Pre-tx: 26.9 (8.8)G2 Post-tx:14.3 (10.0)G2 1 mth FU:13.9 (10.9)G2 3 mth FU: 14.7 (12.1)G2 6 mth FU: 13.4 (11.7)G3 Pre-tx: 29.4 (7.9)G3 Post-tx:13.2 (12.1)G3 1 mth FU: 13.2 (12.2)G3 3 mth FU: 10.3 (9.3)G3 6 mth FU: 4.5 (6.9)G4 Pre-tx: 22.1 (9.5)G4 Post-tx:17.5 (11.6)G4 1 mth FU: 15.0 (11.3)G4 3 mth FU: 14.9 (12.3)Additional results presented in graphsWork/Social Adjustment Mean change in G1 + G2 + G3 vs. G4Post, p=0.0021 mth FU, p=0.0063 mth FU, p=0.005 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Marshall et al., 2001[64](#_ENREF_64) | G1: Paroxetine20 mg/day G2: Paroxetine40 mg/dayG3: Placebo | MADRSAdjusted Mean Differences (95% CI) G1 vs. G3-5.6 (-8.0 to -3.3)p<0.001G2 vs. G3-5.1 (-7.4 to -2.8)p<0.001 | NR | SDSAdjusted Mean Differences (95% CI) G1 vs. G3-2.4 (-4.1 to -0.8)p<0.005G2 vs. G3-2.0 (-3.7 to -0.3)p<0.001 | NR |
| Martenyi et al., 2002[61](#_ENREF_61)Martenyi et al., 2006[173](#_ENREF_173) | G1: Fluoxetine20 to 80 mg/dayG2: Placebo | MADRSChanges from Pre-tx to Post-txLeast Square Means (SE), p-valueG1: -6.5 (0.45)G2: -3.5 (0.75)p<0.001HAM-AChanges from Pre-tx to Post-txLeast Square Means (SE), p-valueG1: -8.7 (0.48)G2: -5.7 (0.79)p=0.001Hopkins 90-Item Symptom Checklist-Revised (SCL-90-R)Changes from Pre-tx to Post-txLeast Square Means (SE), p-valueG1: -51.8 (4.40)G2: -36.4 (7.20)p=0.058 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Martenyi et al., 2007[62](#_ENREF_62) | G1: Fluoxetine20 mg/dayG2: Fluoxetine40 mg/dayG3: Placebo | MADRSMean change from baseline (SE) (Completer analysis)G1: -5.05 (0.82)G2: -5.04 (0.84)G3: -3.45 (1.14)p =0 .463HAMAMean change from baseline (SE) (Completer analysis)G1: -9.12 (0.61)G2: -9.16 (0.62)G3: -7.67 (0.84)p=.296 |   |   |   |
| Maxwell et al., 2016[124](#_ENREF_124) | G1: MESTG2: CPT | BDI-IIMean (SD)G1 Pre-tx:26.13 (11.31)G1 Post-tx:20.25 (16.03)G1 3 mth FU: 18.13 (13.27)G2 Pre-tx:23.63 (16.27)G2 Post-tx:14.75 (10.99)G2 3 mth FU: 11.38 (11.08)Cohen’s d = .40 | NR | GAFMean (SD)G1 Post-tx:67.25 (16.60)G2 Post-tx:69.44 (10.04)Cohen’s d = -0.16 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| McDonagh et al., 2005[39](#_ENREF_39) | G1: CBT-mixed (Exposure and cognitive restructuring therapy)G2: PCTG3: WL | BDIMean (SD)G1 Pre-tx: 18.9 (9.6)G1 Post-tx: 12.9 (12.5)G2 Pre-tx: 17.0 (7.7)G2 Post-tx: 10.8 (9.5)G3 Pre-tx: 20.9 (7.8)G3 Post-tx: 19.0 (11.3)Group X Time, p>0.10STAIMean (SD)G1 Pre-tx: 53.5 (10.4)G1 Post-tx: 46.2 (13.9)G2 Pre-tx: 54.5 (9.2)G2 Post-tx: 46.4 (12.2)G3 Pre-tx: 54.6 (9.6)G3 Post-tx: 51.5 (9.7)Group X Time, p<0.10 | QOLIMean (SD)G1 Pre-tx: 36.1 (15.9)G1 Post-tx: 39.5 (17.0)G2 Pre-tx: 35.2 (15.3)G2 Post-tx: 39.0 (12.6)G3 Pre-tx: 36.8 (13.2)G3 Post-tx: 37.2 (14.7)Group X Time, p>0.10 | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| McGovern et al., 2015[27](#_ENREF_27) | G1: ICBT plus SC, manual-guided therapy focused on PTSD andsubstance use. G2: IAC plus SC, (focused exclusively onsubstance use and recovery) (arm not eligible)G3: SC (intensive out-patient program services) | Positive toxicology, n (%)G1 Pre-tx: 16 (21.9)G1 Post-tx (6 month): 10(18.5)G3 Pre-tx: 15 (20.8)G3 Post-tx (6 month):19(38.8)Difference between G1 and G3, p <0.05Parameter Estimate and CIs for ANCOVAG1 vs. G3, 1.13 (95% CI, 0.18 to 2.08)Effect sizeG1 vs. G2: -0.45ASI-Drug, Mean (SD)G1 Pre-tx: 0.13 (0.09)G1 Post-tx (6 month): 0.08(0.08)G3 Pre-tx: 0.15 (0.09)G3 Post-tx (6 month):0.09(0.09)Difference between G1 and G3, NSParameter Estimate and CIs for ANCOVAG1 vs. G3, -0.01 (95% CI, -0.04 to 0.02)Effect sizeG1 vs. G2: -0.13ASI-alcohol, Mean (SD)G1 Pre-tx: 0.21 (0.22)G1 Post-tx (6 month): 0.15 (0.19) | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Mills et al., 2012[20](#_ENREF_20) | G1: COPE, a modification of Concurrent Treatment of PTSD and Cocaine Dependence. (motivational enhancement, psychoeducation, in vivo exposure, imaginal exposure, and cognitive therapy)G2: TAU  | BDI-IIMean (95% CI)G1 Pre-tx: 36.07 (33.17 to 38.97)G1 Post-tx: 24.44 (19.29 to 29.59)Mean difference Pre-tx to FU: -11.64 (-17.08 to -6.19), p < 0.001G2 Pre-tx: 31.69 (28.08, 35.30)G2 Post-tx: 24.78 (20.15, 29.41)Mean difference Pre-tx to Post-tx: -6.90 (-10.84, -2.97), p < 0.001Between group difference Pre-tx to Post-tx: -4.73 (-11.76, 2.29), NSTreatment X Time Interaction: X2 = 1.31, p = 0.26STAIMean (95% CI)G1 Pre-tx: 54.69 (51.16, 58.22)G1 Post-tx: 46.44 (42.09 to 50.79)Mean difference Pre-tx to Post-tx: -8.25 (-13.64 to -2.86), p < 0.001G2 Pre-tx: 50.42 (46.89 to 53.95)G2 Post-tx: 47.50 (43.15 to 51.85)Mean difference Pre-tx to Post-tx: -2.91 (-7.16 to 1.34), NS | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Mills et al., 2012[20](#_ENREF_20) |   | Between group difference Pre-tx to post-tx: -5.34 (-12.47 to 1.80), NSTreatment X Time Interaction: X2 = 2.69, p = 0.10Number of Drug Classes Used Mean (95% CI)G1 Pre-tx: 3.71 (3.32 to 4.10)G1 Post-tx: 2.13 (1.68 to 2.58)Mean difference Pre-tx to Post-tx: 0.57 (0.46 to 0.72), p < 0.001G2 Pre-tx: 3.81 (3.40 to 4.22)G2 Post-tx: 2.28 (1.71 to 2.85)Mean difference Pre-tx to post-tx: 0.60 (0.47 to 0.76), p<0.001Between group difference Pre-tx to post-tx: 0.96(0.69, 1.34), NSTreatment X Time Interaction: X2 = 0.10, p = 0.76Number of Dependence Criteria MetMean (95% CI)G1 Pre-tx: 5.33 (5.09 to 5.57)G1 Post-tx: 2.27 (1.58 to 2.96)Mean difference Pre-tx to Post-tx: 0.43 (0.31 to 0.58), p < 0.001 |   |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Mills et al., 2012[20](#_ENREF_20) |   | G2 Pre-tx: 5.58 (5.36 to 5.80)G2 Post-tx: 2.98 (2.27 to 3.69)Mean difference Pre-tx to post-tx: 0.52 (0.41 to 0.66), p>0.001Between group difference Pre-tx to post-tx: 0.85 (0.60 to 1.21), NSTreatment X Time Interaction: X2 = 0.00, p >0.99 |   |   |   |
| Monnelly et al., 2003[167](#_ENREF_167) | G1: Risperidone0.5 to 2.0mg/dayG2: Placebo | NR | NR | NR | NR |
| Monson et al., 2006[1](#_ENREF_1) | G1:CBT, cognitive processing therapyG2: WL | BDIMean (SE)G1 Pre-tx: 25.39 (1.8)G1 Post-tx: 17.42 (1.6)G1 1 mth FU: 18.75 (1.9)G2 Pre-tx: 28.53 (1.6)G2 Post-tx: 27.06 (1.4)G2 1 mth FU: 23.92 (1.8)Group X Time, NSSTAIMean (SE)G1 Pre-tx: 54.38 (2.1)G1 Post-tx: 46.92 (2.1)G1 1 mth FU: 47.51 (2.4)G2 Baseline: 55.62 (1.8)G2 Postassessment: 58.16 (2.0)G2 1-month followup: 56.98 (2.3)Group X Time, p<0.01 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Monson et al., 2012[22](#_ENREF_22) | G1: CBCT, manualized cognitive-behavioral conjoint therapy for PTSD delivered in a couple therapy format G2: WL | Beck DepressionMean (95% CI)G1 Pre-tx: 24.36 (19.59 to 29.12)G1 Post-tx: 12.16 (6.35 to 17.96)Change: -12.20 (-19.10 to -5.31)Effect size Hedge g: 1.16 (0.40 to 1.89)G2 Pre-tx: 22.60 (17.88 to 27.32)G2 Post-tx: 20.32 (14.79 to 25.85)Change: -2.29 (-6.37 to -1.79)Effect size Hedge g: 0.17 (-0.13 to 0.47)Change Difference Mean Between Groups: -9.91 (-17.22 to -2.60)Effect size Hedge g: 0.83 (0.10 to 1.54)Treatment X Time Interaction, t (40, 7) = -2.87, p = 0.007State-Trait Anxiety ScaleMean (95% CI)G1 Pre-tx: 49.25 (43.67 to 54.82)G1 Post-tx: 38.65 (31.97 to 45.32)Change: -10.60 (-19.04 to -2.16)Effect size Hedge g: 0.84 (0.17 to 1.49)G2 Pre-tx: 50.90 (45.47 to 56.33)G2 Post-tx: 51.73 (45.47 to 57.99)Change: 0.84 (-4.40 to 6.08)Effect size Hedge g: -0.06 (-0.41 to 0.29)Change Difference Mean Between Groups: -11.43 (-20.55 to -2.31)Effect size Hedge g: 0.85 (0.13 to 1.57)Treatment X Time Interaction, t (44) = -2.62, p = 0.01 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Moradi et al., 2014[160](#_ENREF_160) | G1: MEmory Specificity Training (MEST) G2: Control, no additional contact | BDI-IITreatment X Time Interaction, NS | NR | NR | NR |
| Morath et al., 2014[55](#_ENREF_55) | G1: NETG2: WL | HAM-DMean (SD)G1 Pre-tx: 22.82 (11.73)G1 Post-tx: 17.00 (9.81)G1 1 year post-tx:17.63 (9.84)G2 Pre-tx: 25.94 (6.55)G2 Post-tx: 24.18 (9.21)Treatment X Time Interaction at post-tx, F (1, 32) = 0.89, p = 0.35SOMSMean (SD)G1 Pre-tx: 25.12 (10.55)G1 Post-tx: 19.18 (14.93)G1 1 year post-tx:16.81 (10.00)G2 Pre-tx: 23.00 (12.75)G2 Post-tx: 26.31 (12.38)Treatment X Time Interaction at post-tx, F (1, 32) = 6.19, p = 0.02 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Mueser et al., 2008[7](#_ENREF_7) | G1: CBT-mixed (CBT for PTSD) G2: UC | BDI-IIMean (SD)G1 Pre-tx: 31.48 (13.24)G1 Post-tx: 21.91 (11.52)G1 3 mth FU: 21.67 (13.32)G1 6 mth FU: 25.02 (12.85)G2 Pre-tx: 31.76 (13.76)G2 Post-tx: 27.70 (14.75)G2 3 mth FU: 30.66 (15.26)G2 6 mth FU: 31.30 (13.50)Group effect, p<0.001BAIMean (SD)G1 Pre-tx: 48.29 (13.04)G1 Post-tx: 42.59 (12.95)G1 3 mth FU: 41.10 (14.29)G1 6 mth FU: 43.58 (12.03)G2 Pre-tx: 49.68 (13.26)G2 Post-tx: 45.81 (14.16)G2 3 mth FU: 48.04 (15.62)G2 6 mth FU: 47.84 (13.73)Group effect, p =0.03 | SF-12 - Physical Mean (SD)G1 Pre-tx: 39.81 (11.63)G1 Post-tx: 39.23 (11.26)G1 3 mth FU: 39.17 (13.61)G1 6 mth FU: 38.89 (13.44)Group effect, p=.002G2 Pre-tx: 40.74 (11.54)G2 Post-tx: 39.34 (12.98)G2 3 mth FU: 38.14 (11.59)G2 6 mth FU: 35.81 (10.72)Group effect, p=0.002 | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Mueser et al., 2008[7](#_ENREF_7)(continued) |   | Brief Psychiatric Rating ScaleMean (SD)G1 Pre-tx: 43.92 (7.69)G1 Post-tx: 39.63 (10.00)G1 3 mth FU: 40.57 (7.33)G1 6 mth FU: 41.78 (6.81)G2 Pre-tx: 43.77 (7.42)G2 Post-tx: 42.25 (7.59)G2 3 mth FU: 43.97 (10.37)G2 6 mth FU: 46.60 (11.56)Group effect, p =0.02 | SF-12-Mental Mean (SD)G1 Pre-tx:: 29.35 (9.57)G1 Post-tx: 33.81 (11.02)G1 3 mth FU: 33.92 (11.03)G1 6 mth FU: 31.19 (9.12)G2 Pre-tx: 29.37 (9.05)G2 Post-tx: 33.75 (10.93)G2 3 mth FU: 29.99 (11.44)G2 6 mth FU: 26.66 (10.01)Group effect, p=0.13 |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Nacasch et al., 2011[15](#_ENREF_15) | G1: CBT, exposure-based therapy (PE)G2: TAU | BDIMean (SD)G1 Pre-tx: 26.0 (7.9)G1 Post-tx: 13.2 (7.6)G2 Pre-tx: 31.4 (8.8)G2 Post-tx: 26.8 (10.7)Post-txTreatment X Time, NSG1 vs. G2, p=0.007STAI - StateMean (SD)G1 Pre-tx: 59.5 (11.6)G1 Post-tx: 44.3 (11.0)G2 Pre-tx: 60.9 (13.3)G2 Post-tx: 62.0 (12.3)Post-txTreatment X Time, p=0.007G1 vs. G2, p<0.001STAI - TraitMean (SD)G1 Pre-tx: 59.5 (8.3)G1 Post-tx: 47.7 (12.6)G2 Pre-tx: 61.0 (10.9)G2 Post-tx: 61.7 (12.5)Post-txTreatment X Time, p=0.016G1 vs. G2, p=0.017 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Neuner et al., 2004[161](#_ENREF_161) | G1: CBT, exposure-based therapy (NET)G2: Supportive CounselingG3: Psycho-education About the nature and prevalence of PTSD | Self-Reporting Questionnaire 20 (SRQ-20)Mean (SD)G1 Pre-tx: 15.6 (2.9)G1 Post-tx: 13.1 (5.1)G1 4 mth FU: 11.9 (4.9)G1 1 year FU: 11.0 (5.1)G2 Pre-tx: 16.5 (2.7)G2 Post-tx: 14.3 (5.0)G2 4 mth FU: 12.8 (3.9)G2 1 year FU: 12.4 (4.8)G3 Pre-tx: 18.6 (2.0)G3 Post-tx: 15.3 (3.2)G3 4 mth FU: 15.1 (2.6)G3 1 year FU: 14.4 (4.1)Group X Time, NSG1 vs. G2, p<0.01G1 vs. G3, NS | SF-12, Psychological health ScaleMean (SD)G1 Pre-tx: 0.27 (0.12)G1 Post-tx: 0.36 (0.19)G1 4 mth FU: 0.38 (0.12)G1 1 year FU: 0.44 (0.19)G2 Pre-tx: 0.34 (0.11)G2 Post-tx: 0.33 (0.21)G2 4 mth FU: 0.33 (0.14)G2 1 year FU: 0.36 (0.14)G3 Pre-tx: 0.23 (0.15)G3 Post-tx: 0.33 (0.19)G3 4 mth FU:0.37 (0.14)G3 1 year FU: 0.35 (0.17)Group X Time, NSG1 vs. G2, NSG1 vs. G3, NS |   | NR |
| Neuner et al., 2008[54](#_ENREF_54) | G1: CBT, exposure based (NET)G2: Flexible Trauma Counseling G3: No-treatment monitoring group | NR | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Neuner et al., 2010[53](#_ENREF_53) | G1: CBT, exposure based (NET)G2: UC | Hopkins Symptom Checklist - 25 Depression ScaleMean (SD)G1 Pre-tx: 3.0 (0.4)G1 Post-tx: 2.6 (0.6)G2 Pre-tx: 3.0 (0.5)G2 Post-tx: 2.9 (0.5)Group X Time, NS | NR | NR | NR |
| Nijdam et al., 2012[154](#_ENREF_154) | G1: Eclectic psychotherapyG2: EMDR | HADS - DepressionMean Estimated Differences @ first f/u:3.58 (1.68 to 5.49)p<0.001Mean Estimated Differences @ 2ndf/u: 1.47 (-0.44 to 3.39)p= 0.13HADS-AnxietyMean Estimated Differences @ 2nd f/u:3.74 (2.03 to 5.46)p<0.001HADS-AnxietyMean Estimated Differences @ 2nd f/u:0.80 (-0.93 to 2.50)p=0.36MDD in G1% @ baseline: 67.1% @ 1st f/u: 36.4% @ 2nd f/u: 19 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Nijdam et al., 2012[154](#_ENREF_154)(continued) |   | MDD in G2% @ baseline: 52.9% @ 1st f/u: 13.7% @ 2nd f/u: 14.6MDD between group difference @ 1st f/u: p<0.05MDD between group difference @ 2nd f/u: p=0.57Anxiety in G1% @ baseline: 20% @ 1st f/u: 9.1% @ 2nd f/u: 11.9Anxiety in G2% @ baseline: 11.4% @ 1st f/u: 9.8% @ 2nd f/u: 10.4MDD between group difference @ 1st f/u: p=0.91MDD between group difference @ 2nd f/u: p=0.82 |   |   |   |
| Panahi et al., 2011[71](#_ENREF_71) | G1: Sertraline50 to 200 mg/dayG2: Placebo | NR | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Petrakis et al., 2011[185](#_ENREF_185) | G1: Paroxetine (40 mg/day)+ Naltrexone (50 mg/day) Participants who could not tolerate the highest dose were brought to lower doses.G2: Paroxetine (40 mg/day) +PlaceboParticipants who could not tolerate the highest dose were brought to lower doses.G3: Desipramine (200 mg/day) + Naltrexone (50 mg/day) Participants who could not tolerate the highest dose were brought to lower doses.G4: Desipramine (200 mg/day + PlaceboParticipants who could not tolerate the highest dose were brought to lower doses. | HAM-DMean(SE)G1 Pre-tx: 13.273 (1.112)G1 Post-tx:9.328 (1.256)G2 Pre-tx: 10.950 (1.167)G2 Post-tx:8.238 (1.299)G3 Pre-tx: 11.195 (1.132)G3 Post-tx: 8.563 (1.201)G4 Pre-tx: 13.167 (1.065)G4 Post-tx: 8.943 (1.117)Time effect, p<0.00Group X Time, NS | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Polusny et al., 2015[136](#_ENREF_136) | G1: 8 weekly group sessions and a daylong retreat. 1st session was an orientation that included rational and psychoeducation. 7 sessions of mindfulness therapy and 1 6.5 hour retreat. G2: Group Sessions | PHQ-9Mean (95% CI)G1 Pre-tx: 15.5 (13.9 to 17.0)G1 Post-tx: 13.6 (12.0 to 15.1)G1 2 month followup: 13.3 (11.7 to 15.0)G2 Pre-tx: 14.6 (13.1 to 16.2)G2 Post-tx: 13.9 (12.3 to 15.4)G2 2 month followup: 13.8 (12.2 to 15.4)Post-tx, Between group mean difference: 1.17 (-0.22 to 2.56), p = .12 month, Between group mean difference: 1.34 (-0.07 to 2.75, p=0.06Clinically significant improvement: Posttx Mindfulness - 15 (29.4%)Posttx PCT - 11 (19.4%)2 month Mindfullness - 13 (27.7%)2 month PCT - 13 (22.8%)Mean difference at Posttx: 9.8%, p = .24Mean difference at 2 months: 4.9%, p= .57 | WHOQOL-BREFMean (95% CI)G1 Pre-tx: 75.6 (71.6 to 79.7)G1 Post-tx: 80.7 (76.5 to 84.8)G1 2 month followup: 80.2 (75.9 to 84.4)G2 Pre-tx: 76.4 (72.3 to 80.4)G2 Post-tx: 78.5 (74.4 to 82.6)G2 2 month followup: 75.8 (71.7 to 79.9)Post-tx, Between group mean difference: 3.1, p = 0.082 month, Between group mean difference: 5.22, p=0.004 | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Raskind et al., 2003[74](#_ENREF_74) | G1: Prazosin2 to 10 mg/dayG2: Placebo | NR | NR | NR | NR |
| Raskind et al., 2007[75](#_ENREF_75) | G1: Prazosin2 to 15 mg at bedtimeG2: Placebo | HAM-DMean (SD)G1 Pre-tx: 18.3 (8.8)G1 Post-tx: 12.7 (7.7)G2 Pre-tx: 15.3 (7.8)G2 Post-tx: 14.7 (7.1)G1 vs. G2 Change, p=0.08 | NR | NR | NR |
| Raskind et al., 2013[76](#_ENREF_76) | G1: Prazosin 1 to 5 mg/day morning dose, 1 to 20mg/day bedtime doseG2: Placebo  | HAM-DAdjusted Means (95% CI)G1 Pre-tx: 11.9 (9.5 to 14.3)G1 Post-tx: 10.0 (7.5 to 12.5)G2 Pre-tx: 14.7 (12.4 to 17.0)G2 Post-tx: 14.7 (12.3 to 17.1)Between Group Difference in Change from Baseline: 2.0 (-0.8 to 4.8), t = 1.39, p = 0.17 | NR | NR | NR |
| Reger et al., 2016[18](#_ENREF_18) | G1: VREG2: PEG3: WL (minimum attention) | BDI-IIMean (SD)G1 Pre-tx: 27.87 (9.19)G1 Post-tx: 18.50 (12.70)G1 12 week: 20.04 (12.41)G1 26 week: 18.59 (11.03)G2 Pre-tx: 28.02 (11.18)G2 Post-tx: 17.06 (16.18)G2 12 week: 13.70 (13.52)G2 26 week: 14.42 (13.38)G3 Pre-tx: 27.67(9.99)G3 Post-tx: 25.63 (12.87) | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Reger et al., 2016[18](#_ENREF_18)(continued) |   | G1 vs. G3 Post-tx Differences: -7.87 (95% CI, -11.89 to -3.85), p <0.001, ES = -0.78 (95% CI, -1.18 to -0.38)G2 vs. G3 Post-tx Differences: -9.09 (95% CI, -12.97 to -5.20), p <0.001, ES = -0.90 (95% CI, -1.29 to -0.52)G1 vs. G2 Post-tx Differences: 1.22 (95% CI, -3.01 to 5.44), p = 0.714, ES = 0.12 (95% CI, -0.30 to 0.54)G1 vs. G2 12 week Differences: 4.46 (95% CI, -0.05 to 8.98), p = 0.974, ES = 0.44 (95% CI, -0.01 to 0.89)G1 vs. G2 26 week Differences: 4.63 (95% CI, -0.32 to 9.58), p = 0.967, ES = 0.46 (95% CI, -0.03 to 0.95BAIMean (SD)G1 Pre-tx: 24.57 (11.19)G1 Post-tx: 17.17 (12.80)G1 12 week: 19.28 (14.92)G1 26 week: 15.24 (12.19)G2 Pre-tx: 22.11 (9.34)G2 Post-tx: 13.28 (12.11)G2 12 week: 11.44 (11.79)G2 26 week: 9.83 (10.02) |   |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Reger et al., 2016[18](#_ENREF_18)(continued) |   | G3 Pre-tx: 23.81 (11.09)G3 Post-tx: 18.83 (11.93)G1 vs. G3 Post-tx Differences: -5.31 (95% CI, -9.37 to -1.25), p = 0.005, ES = -0.50 (95% CI, -0.89 to -0.12)G2 vs. G3 Post-tx Differences: -5.46 (95% CI, -9.40 to -1.52), p = 0.003, ES = -0.52 (95% CI, -0.89 to -0.14)G1 vs. G2 Post-tx Differences: 0.15 (95% CI, -4.14 to 4.44), p = 0.527, ES = 0.01 (95% CI, -0.39 to 0.42)G1 vs. G2 12 week Differences: 3.51 (95% CI, -1.08 to 8.09), p = 0.933, ES = 0.33 (95% CI, -0.10 to 0.77)G1 vs. G2 26 week Differences: 3.01 (95% CI, -2.02 to 8.03), p = 0.880, ES = 0.28 (95% CI, -0.19 to 0.76 |   |   |   |
| Reich et al., 2004[84](#_ENREF_84) | G1: Risperidone0.5 to 8 mg/dayG2: Placebo | NR | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Resick et al., 2002[3](#_ENREF_3)Resick et al., 2003[125](#_ENREF_125)Resick et al., 2012[126](#_ENREF_126) | G1: CBT, cognitive processing therapyG2: CBT, exposure-based therapy (PE)G3: WL | BDIMean (SD)G1 Pre-tx: 23.70 (10.39)G1 Post-tx: 12.73 (11.17)G1 3 mth FU: 13.22 (11.64)G1 9 mth FU: 14.17 (11.85)G1 LTFU: 9.41 (11.13)G2 Pre-tx: 24.03 (8.88)G2 Post-tx: 16.00 (11.06)G2 3 mth FU: 16.49 (11.62)G2 9 mth FU: 16.41 (11.37)G1 LTFU: 12.06 (12.68)G3 Pre-tx: 23.33 (8.07)G3 Post-tx: 22.62 (8.59)G3 3 mth FU: 22.62 (8.59)G3 9 mth FU: 22.62 (8.59)Posttreatment differences, p<0.00013 mth FU differences, p<0.00019 mth FU differences, p<0.0001LTFU differences, NS | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Resick et al., 2015[127](#_ENREF_127), [128](#_ENREF_128) | G1: CPT-C (Includes only the cognitive component of CPT)G2: PCT | BDI-IIMean (SE) G1 Pre-tx: 27.9 (10.2)G1 Post-tx: 19.9 (1.4)G1 6-month followup: 21.1 (1.8)G1 12-month followup: 22.7 (2.1)G2 Pre-tx: 27.9 (12.2)G2 Post-tx: 23.7 (1.4)G2 6-month followup: 24.7 (1.7)G2 12-month followup: 25.8 (2.1)Piecewise linear model for BDI-II during followupG1: .57 (.44) (.11), p =.197G2: .22 (.42), p = .608Difference: .35 (.60), p = .555Between group effect sizes (d):Baseline to posttreatment: -.3Baseline to 6 months: -.3Baseline to 1 year: -.3 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Rothbaum et al., 1997[45](#_ENREF_45) | G1: EMDRG2: WL | BDIMean (SD)G1 Pre-tx: 21.4 (9.6)G1 Post-tx: 7.3 (5.5)G1 3 mth FU: 7.9 (5.3)G2 Pre-tx: 34.8 (13.8)G2 Post-tx: 30.4 (15.7)G1 vs. G2, p<0.05STAI--StateMean (SD)G1 Pre-tx: 50.4 (10.6)G1 Post-tx: 31.8 (14.7)G1 3 mth FU: 37.3 (14.3)G2 Pre-tx: 63.1 (21.0)G2 Post-tx: 48.5 (15.5)STAI-TraitMean (SD)G1 Pre-tx: 53.5 (10.9)G1 Post-tx: 35.0 (14.3)G1 3 mth FU: 37.3 (14.3)G2 Pre-tx: 64.9 (11.1)G2 Post-tx 58.8 (11.1)Post treatment G1 vs. G2, NS | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Rothbaum et al., 2005[13](#_ENREF_13) | G1: CBT, exposure-based therapy (PE)G2: EMDRG3: WL | BDIMean (SD)G1 Pre-tx: 16.70 (8.18)G1 Post-tx: 4.65 (4.99)G1 6 mth FU: 4.44 (5.07)G2 Pre-tx: 25.95 (7.11)G2 Post-tx: 10.70 (11.45)G2 6 mth FU: 10.53 (10.92)G3 Pre-tx: 24.05 (10.50)G3 Post-tx: 22.20 (10.55)Posttreatment G1 & G2 vs. G3, p<0.001Posttreatment G1 vs G2, p=NS6 mth FU G1 vs G2, p=NSSTAI-StateMean (SD)G1 Pre-tx: 43.33 (12.59)G1 Post-tx: 30.00 (10.44)G1 6 mth FU: 29.19 (8.79)G2 Pre-tx: 51.10 (11.05)G2 Post-tx: 32.60 (11.62)G2 6 mth FU: 38.89 (14.54) | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Rothbaum et al., 2005[13](#_ENREF_13)(continued) |   | G3 Pre-tx: 46.58 (13.48)G3 Post-tx: 49.00 (13.73)Posttreatment G1 & G2 vs. G3, p<0.001Posttreatment G1 vs G2, p=NS6 mth FU G1 vs G2, p=NSSTAI-TraitG1 Pre-tx: 48.72 (8.62)G1 Post-tx: 35.56 (9.88)G1 6 mth FU: 34.19 (7.52)G2 Pre-tx: 56.80 (10.95)G2 Post-tx: 41.10 (14.48)G2 6 mth FU: 41.44 (13.26)G3 Pre-tx: 53.42 (13.07)G3 Post-tx: 53.95 (13.01)Posttreatment G1 & G2 vs. G3, p<0.001Posttreatment G1 vs G2, p=NR6 mth FU G1 vs. G2, NR |   |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Ruglass et al., 2017 [143](#_ENREF_143) | G1: COPEG2: Relaspe PreventionG3: AMCG | SUIMean (SD)G1 Pre-tx: 3.92 (2.69)G1 Post-tx: 1.60 (2.46)Change: -2.31 (95% CI, -3.23 to -1.39), p <0.001G2 Pre-tx: 4.05 (2.35)G2 Post-tx: 0.40 (0.52) Change: -3.28 (95% -4.03 to -2.53), p <0.001G3 Pre-tx: 3.79 (2.27)G3 Post-tx: 2.85 (2.48)Change: NR, nsTreatment X Time Interaction, p <0.001Between group differencesG1 vs G3: -0.97 (95%CI -1.72 to -0.22), p = 0.01G2 vs G3: -2.07 (95%CI -2.92 to -1.21), p <0.001G1 vs G2: -1.10 (95%CI -2.18 to -0.02, p =0.047 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Sannibale et al. 2013[146](#_ENREF_146) | G1: IT (Integrated CBT for PTSD and AUD)G2: AS, (CBT for AUD plus supportive counseling) | BDI-IIG1 Pre-tx: 30.37 (13.99)G1 Post-tx: 25.13 (17.96) G1 Followup 5 months: 26.79 (18.35)G1 Followup 9 months: 23.38 (15.14)G2 Pre-tx: 28.50 (9.15)G2 Post-tx: 25.45 (12.52) G2 Followup 5 months: 25.33 (12.53)G2 Followup 9 months: 22.24 (14.82)Treatment group\*time interaction nsSTAI-SG1 Pre-tx: 55.89 (14.78)G1 Post-tx: 48.83 (15.90) G1 Followup 5 months: 53.17 (14.41)G1 Followup 9 months: 52.00 (14.74)G2 Pre-tx: 55.96 (10.80)G2 Post-tx: 53.64 (10.47) G2 Followup 5 months: 54.71 (14.30)G2 Followup 9 months: 49.81 (14.76)Treatment group\*time interaction ns | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Sannibale et al. 2013[146](#_ENREF_146)(continued) |   | AUD diagnosis n (%)G1 Pre-tx: 33 (100)G1 Post-tx: 16 (64) G1 Followup 5 months: 10 (44)G1 Followup 9 months: 14 (52)G2 Pre-tx: 29 (100)G2 Post-tx: 12 (50) G2 Followup 5 months: 7 (33)G2 Followup 9 months: 9 (43)Treatment X time interaction ns |   |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Sautter et al., 2015[131](#_ENREF_131) | G1: SATG2: PFE | CES-DMean (SE)G1 Pre-tx: 31.10 (2.18)G1 Post-tx: 24.70 (2.43)G1 12-week followup:22.13 (2.43)G2 Pre-tx: 30.21 (2.21)G2 Post-tx: 28.48 (2.45)G1 12 week followup: 28.22 (2.48)Treatment X TimeInteraction at post-tx, t (79) = 1.45, p = 0.15Treatment X Time  Interaction at 12 week followup, t (79) = 2.15, p = 0.04STAI StateMean (SE)G1 Pre-tx: 49.66 (2.37)G1 Post-tx: 39.61 (2.66)G1 12 week followup: 37.69 (2.66)G2 Pre-tx: 47.11 (2.41)G2 Post-tx: 44.58 (2.67)G1 12 week followup: 44.94 (2.71)Treatment X Time Interaction at post-tx, t (79) = 2.10, p = 0.039Treatment X Time Interaction at 12 week followup, t (79) = 2.72, p = 0.008 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Schnurr et al., 2003[139](#_ENREF_139) | G1: Exposure-based, trauma-focused group therapy (psychoeducation, cognitive restructuring, relapse prevention, and coping skills training) G2: Present-centered group Therapy(avoided trauma-focused references, cognitive restructuring, and other trauma-focused group therapy components) | NR | Only reported that there was no change on the Quality of Life Inventory. SF-36 – MentalMean (SE) G1: Pre-tx: 30.72 (0.86)G1 7 mth FU: 31.84 (0.73)G1 12 mth FU: 30.92 (0.81)Change at 7 mths, p>0.05Change at 12 mths, p>0.05G2 Pre-tx: 30.54 (0.85)G2 7 mth FU: 30.75 (0.73)G2 12 mth FU: 31.83 (0.79)Change at 7 mths, p>0.05Change at 12 mths, p>0.05SF-36- Physical G1 Pre-tx: 41.78 (0.94)G1 7 mth FU: 40.35 (0.68)G1 12 mth FU: 40.24 (0.73) | GHQMean (SE)G1 Pre-tx: 32.69 (0.55)G1 7 mth FU: 31.16 (0.49)G1 12 mth FU: 31.88 (0.53)Change at 7 mths, p<0.001Change at 12 mths, p<0.05G2 Pre-tx: 33.45 (0.54)G2 7 mth FU: 31.62 (0.49)G2 12 mth FU: 31.19 (0.53)Change at 7 mths, p<0.01Change at 12 mths, p<0.001Treatment Effect, NSTreatment X Cohort, NS | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Schnurr et al., 2003[139](#_ENREF_139)(continued) |   |   | Change at 7 mths, p>0.05Change at 12 mths, p>0.05G2 Pre-tx: 40.06 (0.95)G2 7 mth FU: 39.96 (0.68)G2 12 mth FU: 38.93 (0.71)Change at 7 mths, p>0.05Change at 12 mths, p<0.01Treatment Effect, NSTreatment X Cohort, NS |   |   |
| Schnurr et al., 2007[138](#_ENREF_138) | G1: CBT, exposure-based therapy (PE)G2: PCT | BDIBaseline Mean (95% CI)G1: 25.3 (23.8 to 26.9)G2: 23.9 (22.4 to 25.5)Least Means (95% CI)Immediate posttreatmentG1: 17.4 (15.3 to 19.5)G2: 19.9 (18.0 to 21.9)p=0.043-month followupG1: 18.5 (16.3 to 20.7)G2: 21.1 (19.1 to 23.1)p=0.04 | QOL InventoryBaselineMean (95 % CI)G1: 0.06 (-0.24 to 0.35)G2: 0.09 (-0.26 to 0.44)Least Means (95% CI)Immediate posttreatment G1: 0.56 (0.19 to 0.93) G2: 0.24 (-0.12 to 0.60) NS |  NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Schnurr et al., 2007[138](#_ENREF_138)(continued) |   | 6-month followupG1: 19.2 (17.1 to 21.3)G2: 20.4 (18.2 to 22.7)NSTreatment effect, NSTreatment X Time, NSSTAIBaselineMean (95% CI)G1: 52.1 (49.9 to 54.4)G2: 52.4 (50.2 to 54.7)Least Means (95% CI)Immediate posttreatmentG1: 45.7 (42.6 to 48.7)G2: 50.3 (47.4 to 53.3)p=0.013-month followupG1: 48.8 (45.9 to 51.8)G2: 50.5 (47.7 to 53.3)NS6-month followupG1: 50.4 (47.3 to 53.6)G2: 50.8 (48.0 to 53.6)NSTreatment effect, NSTreatment X Time, p<0.05 | 3-month followupG1: 0.35 (-0.05 to 0.75) G2: 0.22 (-0.14 to 0.60)NS 6-month followupG1: 0.23 (-0.12 to 0.58) G2: 0.14 (-0.26 to 0.53) NSTreatment effect, NSTreatment X Time, NS SF-36-MentalBaselineMean (95% CI)G1: 30.1 (28.4 to 31.7)G2: 30.6 (28.7 to 32.6) Least Means (95% CI)Immediate posttreatment G1: 37.5 (35.0 to 40.0) G2: 33.4 (30.9 to 35.8)p<0.01 |   |   |

| Author, Year | Intervention Groups | Comorbid l Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Schnurr et al., 2007[138](#_ENREF_138)(continued) |   |   | 3-month followupG1: 35.6 (33.2 to 38.1)G2: 33.8 (31.1 to 36.4)NS 6-month followupG1: 35.3 (33.0 to 37.7) G2: 33.4 (30.9 to 35.9)NS Treatment effect, NSTreatment X Time, NSSF-36-PhysicalBaselineMean (95% CI)G1: 38.3 (36.4 to 40.2)G2: 39.7 (37.5 to 41.8) Least Means (95% CI)Immediate posttreatment G1: 38.1 (36.1 to 40.2)G2: 39.5 (37.5 to 41.4)NS |   |   |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Schnurr et al., 2007[138](#_ENREF_138)(continued) |   |   | 3-month followupG1: 39.1 (37.1 to 41.1)G2: 38.8 (36.7 to 40.9)NS 6-month followupG1: 38.8 (36.7 to 40.8) G2: 38.3 (36.2 to 40.5)NS Treatment effect, NSTreatment X Time, NS |   |   |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Schnyder et al., 2011[49](#_ENREF_49) | G1: Eclectic psychotherapyBEPG2: WL (Minimal attention) | HADS - AnxietyMean (SD)G1 Pre-tx:14.4 (2.6)G1 Post-tx:12.2 (4.2)G1 6 mth FU: 11.8 (5.4)G2 Pre-tx:13.8 (2.5)G2 Post-tx:13.5 (3.1)Group Effect, p<0.05HADS - DepressionG1 Pre-tx:13.4 (4.8)G1 Post-tx:10.8 (5.8)G1 6 mth FU: 11.4 (5.6)G2 Pre-tx: 10.7 (3.5)G2 Post-tx: 11.4 (4.2)Group Effect, p<0.05 | NR | NR | NR |
| Simon et al., 2008[174](#_ENREF_174) | G1: Paroxetine12.5 to 62.5 mg/day G2: Placeboand 5 additional sessions of PE | NR | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Sloan et al., 2012[17](#_ENREF_17) | G1: Sertraline 25 to 200mg/day G2: Venlafaxiene 37.5 to 375mg/day Sertraline 25 to 200mg/day | NR | NR | NR | NR |
| Sonne et al., 2016[186](#_ENREF_186) | G1: WETG2: WL | HAM-D (ITT)Mean (SE) G1 Pre-tx: 23.69 (0.55)G1 Post-tx: 22.33 (0.85)Difference: 1.36 (0.79), p =0.08, Effect size: 0.24G2 Pre-tx: 23.69 (0.62)G2 Post-tx: 22.46 (0.89)Difference: 1.23 (0.82), p =0.13, Effect size: 0.22Group difference for difference between pre- and post-treatment ratings:0.13 (1.14), p = 0.91, Effect size: 0.02Group differences at follow up: Regression coefficient, B = 0.19 (95% CI, -1.94 to 2.33), Beta-coefficient = 0.01, SE = 1.09, p = 0.86 | WHO-5 (ITT)Mean (SE) G1 Pre-tx: 12.73 (1.36)G1 Post-tx: 22.21 (2.67)Difference: -9.48 (2.42), p <0.01, Effect size: 0.65G2 Pre-tx: 15.00 (1.64)G2 Post-tx: 17.75 (2.24)Difference: -2.75 (2.16), p =0.20, Effect size: 0.19Group difference for difference between pre- and post-treatment ratings:6.73 (3.24), p = 0.04, Effect size: 0.47 | SDS (ITT)Mean (SE) G1 Pre-tx: 24.65 (0.53)G1 Post-tx: 21.81 (0.88)Difference: 2.84 (0.85), p <0.01, Effect size: 0.48G2 Pre-tx: 22.71 (0.69)G2 Post-tx: 23.20 (0.79)Difference: -0.49 (0.86), p =0.57, Effect size: 0.08Group difference for difference between pre- and post-treatment ratings:3.32 (1.21), p < 0.01, Effect size: 0.56Group differences at follow up: Regression coefficient, B = 2.31 (95% CI, 0.10 to 4.52), Beta-coefficient = 0.16, SE = 1.13, p = 0.04SAS-SR(ITT)Mean (SE) G1 Pre-tx: 2.93 (0.07)G1 Post-tx: 2.68 (0.08)Difference: 0.25 (0.07), p <0.01, Effect size: 0.36 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Sonne et al., 2016[186](#_ENREF_186)(continued) |   | HAM-A (ITT)Mean (SE) G1 Pre-tx: 26.74 (0.68)G1 Post-tx: 26.41 (1.04)Difference: 0.33 (0.97), p = 0.73, Effect size: 0.05G2 Pre-tx: 27.14 (0.72)G2 Post-tx: 26.05 (1.05)Difference: 1.09 (1.00), p =0.28, Effect size: 0.16Group difference for difference between pre- and post-treatment ratings:-0.76 (1.39), p = 0.58, Effect size: 0.11Group differences at follow up: Regression coefficient, B = -0.57 (95% CI, -3.19 to 2.04), Beta-coefficient = -0.03, SE = 1.34, p = 0.67 | Group differences at follow up: Regression coefficient, B = -5.79 (95% CI, -12.05 to 0.46), Beta-coefficient = -0.13, SE = 3.19, p = 0.07 | G2 Pre-tx: 2.96 (0.07)G2 Post-tx: 2.80 (0.08)Difference: 0.16 (0.08), p =0.04, Effect size: 0.23Group difference for difference between pre- and post-treatment ratings: 0.09 (0.11), p = 0.39, Effect size: 0.13Group differences at follow up: Regression coefficient, B = 0.10 (95% CI, -0.09 to 0.29), Beta-coefficient = 0.07, SE = 0.10, p = 0.29GAF-S(ITT)Mean (SE) G1 Pre-tx: 47.43 (0.57)G1 Post-tx: 51.33 (0.93)Difference: -3.90 (0.79), p <0.01, Effect size: 0.68G2 Pre-tx: 48.14 (0.61)G2 Post-tx: 51.82 (0.94)Difference: -3.68 (1.03), p <0.01, Effect size: 0.64Group difference for difference between pre- and post-treatment ratings: 0.22 (1.29), p = 0.86, Effect size: 0.04 |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Sonne et al., 2016[186](#_ENREF_186)(continued) |   | HSCL-25 (ITT)Mean (SE) G1 Pre-tx: 3.03 (0.05)G1 Post-tx: 2.85 (0.07)Difference: 0.18 (0.07), p <0.01, Effect size: 0.39G2 Pre-tx: 3.04 (0.05)G2 Post-tx: 2.94 (0.06)Difference: 0.10 (0.05), p =0.05, Effect size: 0.22Group difference for difference between pre- and post-treatment ratings:0.08 (0.09), p = 0.37, Effect size: 0.17Group differences at follow up: Regression coefficient, B = 0.07 (95% CI, -0.10 to 0.23), Beta-coefficient = 0.05, SE = 0.08, p = 0.42 |   | GAF Group differences at follow up: Regression coefficient, B = 0.06 (95% CI, -2.37 to 2.48), Beta-coefficient = 0.00, SE = 1.24, p = 0.96-F(ITT)Mean (SE) G1 Pre-tx: 48.37 (0.68)G1 Post-tx: 50.28 (0.92)Difference: -1.91 (0.79), p = 0.02, Effect size: 0.29G2 Pre-tx: 49.04 (0.68)G2 Post-tx: 51.91 (0.96)Difference: -2.87 (0.89), p <0.01, Effect size: 0.43Group difference for difference between pre- and post-treatment ratings: 0.96 (1.19), p = 0.42, Effect size: 0.06Group differences at follow up: Regression coefficient, B = 1.22 (95% CI, -1.03 to 3.47), Beta-coefficient = 0.08, SE = 1.15, p = 0.29 |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Sonne et al., 2016[186](#_ENREF_186)(continued) |   | SCL-90 (ITT)Mean (SE) G1 Pre-tx: 2.40 (0.058)G1 Post-tx: 2.35 (0.10)Difference: 0.05 (0.10), p = 0.64, Effect size: 0.06G2 Pre-tx: 2.50 (0.08)G2 Post-tx: 2.53 (0.09)Difference: -0.03 (0.07), p =0.69, Effect size: 0.04Group difference for difference between pre- and post-treatment ratings:0.08 (0.12), p = 0.54, Effect size: 0.10Group differences at follow up: Regression coefficient, B = 0.12 (95% CI, -0.12 to 0.35), Beta-coefficient = 0.07, SE = 0.12, p = 0.31 |   |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Spence et al., 2011[30](#_ENREF_30) | G1: CBT-mixed (Imaginal exposure, Coping skills, Cognitive processing)G2: WL | Patient Health Questionaire-9 itemG1 Pre-tx: 15.61 (4.38)G1 Post-tx: 10.17 (5.65)G1 3 mth FU: 9.91 (6.12)G2 Pre-tx: 15.05 (4.90) G2 Post-tx: 13.84 (4.95)G2 3 mth FU: NRG1 vs. G2, p<0.01Generalized Anxiety Disorder ScaleG1 Pre-tx: 12.91 (4.57)G1 Post-tx: 7.91 (5.98)G1 3 mth FU: 7.26 (5.94)G2 Pre-tx: 11.11 (3.89)G2 Post-tx: 10.63 (3.53)G2 3 mth FU: NRG1 vs. G2 @ 8 weeks:p<0.04\*\* | NR | SDSG1 Pre-tx: 18.17 (6.96)G1 Post-tx: 13.22 (9.42)G1 3 mth FU: 11.30 (9.64)G2 Pre-tx: 19.42 (8.03)G2 Post-tx: 18.11 (6.67)G2 3 mth FU: NRG1 vs G2, p=0.07 | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Stein et al., 2002[80](#_ENREF_80) | G1: Olanzapine10 to 20 mg G2: Placebo | CES -D G1: -5.25 (SD=6.27)G2: 4.88 (SD=9.66)p<.03 | NR | NR | NR |
| Tarrier et al., 1999[129](#_ENREF_129)Tarrier et al., 1999[130](#_ENREF_130) | G1: CBT, exposure-based therapyG2: CBT, cognitive restructuring,Cognitive Therapy | BDI Mean (SD)G1 Pre-tx: 23.93 (10.95)G1 Post-tx: 17.43 (11.88)G1 6-mth FU: 20.41 (10.60)G2 Pre-tx: 27.45 (12.39)G2 Post-tx: 19.03 (13.20)G2 6 mth FU: 20.83 (12.79)G1 vs. G2 differences, NS12-Month FollowupG1 Pre-tx: 23.52 (10.87)G1 12 mth FU: 20.33 (11.40)G2 Pre-tx: 26.90 (12.34)G2 12 mth FU: 20.93 (13.55)G1 vs. G2 differences, NS |  NR | NR | Percentage Back at Work6 Month FollowupOverall: 40%G1: 44%G2: 37% |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Tarrier et al., 1999[129](#_ENREF_129)Tarrier et al., 1999[130](#_ENREF_130)(continued) |   | BAIMean (SD)G1 Pre-tx: 26.86 (10.75)G1 6 mth FU: 23.04 (12.18)G2 Pre-tx: 26.39 (12.05)G2 6 mth FU: 20.66 (12.97)G1 vs. G2 differences, NS12-Month FollowupG1 Pre-tx: 26.76 (10.23)G1 12 mth FU: 20.58 (13.01)G2 Pre-tx: 26.34 (12.32)G2 12 mth FU: 21.54 (14.13)G1 vs. G2 differences, NS |   |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Taylor et al., 2003[133](#_ENREF_133) | G1: CBT, exposure-based therapyG2: EMDRG3: Relaxation Training | BDIMean (SD)G1 Pre-tx: 26.4 (10.0)G1 Post-tx: 16.04 (9.1)G1 FU: 14.4 (11.0)G2 Pre-tx: 23.2 (7.8)G2 Post-tx: 13.0 (10.6)G2 FU: 12.7 (8.9)G3 Pre-tx: 26.3 (11.1)G3 Post-tx: 21.0 (13.8)G3 FU: 16.7 (8.9)Treatment Effects, NSTreatment X Time, NS Time Effect from Post-tx to FU, p 0.01 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| ter Heide et al., 2016[43](#_ENREF_43) | G1: EMDRG2: Stabilisation  | HSCL, anxietyG1 vs. G2, d = 0.09, NSHSCL, depressionG1 vs. G2, d = -0.03, NS | WHOQOL-BREF, physicalG1 vs. G2, d = 0.07, NSWHOQOL-BREF, psychologicalG1 vs. G2, d = 0.07, NSWHOQOL-BREF, social relationshipsG1 vs. G2, d = -0.28, NSWHOQOL-BREF, environmentG1 vs. G2, d = -0.52, NS | NR | NR |
| Tucker et al., 2001[65](#_ENREF_65) | G1: Paroxetine20 to 50mg/dayG2: Placebo | MADRSAdjusted Mean Differences (95% CI), G1 vs. G2-3.9 (-6.4 to -1.2) | NR | SDSAdjusted Mean Differences (95% CI), G1 vs. G2-2.6 (-4.4 to -0.7) | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Tucker et al., 2003[175](#_ENREF_175)Tucker et al., 2004[176](#_ENREF_176) | G1: Citalopram20 to 50 mg/dayG2: Sertraline50 to 200 mg/dayG3: Placebo | RefId 824Systolic BP differenceG1 Pre-tx: 6.66G1 Post-tx: 0.70G2 Pre-tx: 4.20G2 Post-tx: -0.11G3 Pre-tx: 7.25G3 Post-tx: 1.00Between group differences, NSDiastolic BPG1 Pre-tx: 2.28G1 Post-tx: -1.65G2 Pre-tx: 2.22G2 Post-tx: 0.47G3 Pre-tx: 5.60G3 Post-tx: -2.93Between group differences, NS | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Tucker et al., 2003[175](#_ENREF_175)Tucker et al., 2004[176](#_ENREF_176)(continued) |   | Heart rate differenceMean (SD)G1 Pre-tx: 3.22 (5.16)G1 Post-tx:1.65 (3.00)G2 Pre-tx: 2.20 (3.56)G2 Post-tx: 1.69 (3.75)G3 Pre-tx: 0.85 (1.00)G3 Post-tx: 0.57 (2.75)Between group differences, NSBDIG1 Pre-tx: 29.72(13.93)G1 Post-tx: 13.65 (11.06)G2 Pre-tx: 27.09 (12.25)G2 Post-tx: 13.67 (14.56)G3 Pre-tx: 31.60 (9.38)G3 Post-tx: 16.00 (17.21)Between group differences, p value NR |   |   |   |
| Tucker et al., 2007[78](#_ENREF_78) | G1: Topiramate25 to 400mg/day; given 2 times a dayG2: Placebo | HAM-AMean Percentage Change (SD)G1: -53.9 (42.8) G2: -40.0 (44.2)p= 0.331HAM-DMean Percentage Change (SD)G1 -50.7 (45.6) G2 -33.3 (46.8)p= 0.253 | Sexual Functioning ScaleMean Percentage Change (SD)G1: 2.58 (31.2)G2: 16.2 (20.4)p= 0.120 | SDSMean Percentage Change (SD)G1: -30.6 (56.4)G2: -35.4 (61.9) p=0.804 | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Van Dam et al., 2013[262](#_ENREF_262) | G1: SWT plus TAU G2: TAU (regular intensivetreatment program for SUD based on CBT) | TLFB (days abstinent)Mean (SD)G1 Pre-tx: 19.9 (29.3)G1 Post-tx: 76.8 (15.5)G1 Followup 3 months: 61.0 (30.8)G2 Pre-tx: 20.1 (25.4)G2 Post-tx:66.0 (30.3)G2 Followup 3 months: 58.6 (38.4)Treatment X time Interaction, F(2,34) = 0.48, p = 0.620, η2 = 0.15SUD in Remission (Primary SUD diagnosis)N (%)G1 Pre-tx: 1 (5.3)G1 Post-tx: 16.6 (87.4)G2 Pre-tx: 3 (20.0)G2 Post-tx: 10.2 (68.0)G1 vs. G2 post-tx differences NS, p’s>0.23 | NR | NR | NR |
| van den Berg et al., 2015[16](#_ENREF_16) | G1: PEG2: EMDRG3: WL | NR | NR | NR | NR |
| van der Kolk et al., 1994[63](#_ENREF_63) | G1: Fluoxetine20 to 60mg/dayG2: Placebo | HAM-DDifference in Improvement G1 vs. G2 = 7.11ANCOVA ResultsF = -7.11, t = -3.72, p=0.0006 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| van der Kolk et al., 2007[47](#_ENREF_47) | G1: EMDRG2: Fluoxetine10 to 60 mg/dayG3: Placebo | BDI-IIMean (SD) G1 Pre-tx:G1 Post-tx: 9.10 (6.02)G1 6 mth FU: 5.25 (5.23)G2 Pre-tx:G2 Post-tx: 13.00 (8.66)G2 6 mth FU: 14.00 (7.71)G3 Pre-tx:G3 Post-tx: 14.38 (9.74)G3: NATreatment effect, NSPosttreatmentG1 vs. G2, p= 0.08G1 vs. G3, p=0.07G2 vs. G3, p=0.94 FollowupG1 vs. G2, p<.001 | NR | NR | NR |
| van der Kolk et al., 2016[162](#_ENREF_162) | G1: NeurofeedbackG2: WL | NR | NR | IASC is available. Only subscales reported.  | NR |

| Author, Year | Intervention Groups | Comorbid Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| van Emmerik et al., 2008[40](#_ENREF_40) | G1: CBT-Mixed Psychoeducation, prolonged exposure, imaginal exposure, exposure in vivo, cognitive exposureG2: SWT G3: WL | BDIMean (SD)G1 Pre-tx: 20.52 (9.43)G1 Post-tx: 15.31 (9.44)G1 FU: 14.79 (9.48)G2 Pre-tx: 22.55 (10.63)G2 Post-tx: 19.39 (13.38)G2 FU: 18.65 (13.56)G3 Pre-tx: 21.24 (8.88)G3 Post-tx: 20.66 (10.77)G3 FU: 21.17 (11.13)Group X Time EffectG1 vs G2, p=0.51G1+G2 vs G3, p<0.04STAI-StateMean (SD)G1 Pre-tx: 55.44 (11.22)G1 Post-tx: 46.51 (14.32)G1 FU: 46.90 (15.02)G2 Pre-tx: 54.22 (11.90)G2 Post-tx: 47.49 (15.75)G2 FU: 46.70 (15.09)G3 Pre-tx: 57.14 (11.60)G3 Post-tx: 54.06 (12.18)G3 FU: 55.08 (12.83)Group X Time EffectG1 vs. G2, p=0.81G1+G2 vs G3, p=0.05 | NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| van Emmerik et al., 2008[40](#_ENREF_40)(continued) |   | STAI-TraitG1 Pre-tx: 50.54 (8.49)G1 Post-tx: 46.23 (9.80)G1 FU: 48.15 (9.00)G2 Pre-tx: 50.35 (7.33)G2 Post-tx: 47.62 (8.81)G2 FU: 47.19 (8.76)G3 Pre-tx: 53.20 (8.70)G3 Post-tx: 52.23 (7.31)G3: 52.06 (7.28)Group X TimeG1 vs G2, p=0.37G1+G2 vs G3, p=0.20 |   |   |   |
| Wells et al., 2014[19](#_ENREF_19) | G1: Metacognitive therapyG2: PEG3: WL | BDI-IIMean (SD)G1 Pre-tx: 29.9 (5.48)G1 Post-tx: 9.1 (6.79)G1 3 month followup: 12.6 (13.53)Mean difference, post-tx: 20.8 (SE, 3.48), p <0.0005, (95% CI, 12.93 to 28.67)G2 Pre-tx: 32.5 (10.06)G2 Post-tx: 17.9 (13.09)G2 3 month followup: 17.1 (14.59)Mean difference, post-tx: 14.6 (4.18), p = 0.007, (95% CI, 5.16 to 24.04) G3 Pre-tx: 40.7 (10.66)G3 Post-tx: 40 (8.68)G3 3 month followup: NA |  NR | NR | NR |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Wells et al., 2014[19](#_ENREF_19) (continued) |   | Mean difference, post-tx: 0.7 (1.56), p > 0.05, (95% CI, -2.84 to 4.24)Treatment X time interaction, post-tx: F=9.94, p = 0.001Hedge's g:G1 Pre-Post: 1.73G2 Pre-Post: 1.01G1 Pre-FU: 1.01G2 Pre-FU: 0.9ANCOVA group effect: F = 16.53, p < 0.0005G1 vs G3 Pre-Post: 26.09 (SE, 4.63), p < 0.0005, (95% CI, 14.26 to 37.93)G2 vs G3 Pre-Post: 18.45 (4.42), p = 0.001, (95% CI, 7.15 to 29.75)G1 vs G2 Pre-Post: 7.64 (4.15), p > 0.05, (95% CI, -2.96 to 18.25)ANCOVA group effects at followupG1 vs. G2: F = 0.39, p = 0.54BAIMean (SD)G1 Pre-tx: 29.5 (7.69)G1 Post-tx: 8.6 (6.06)G1 3 month followup: 12 (13.57)Mean difference, post-tx: 20.9 (SE = 2.77), p <0.0005, (95% CI, 14.64 to 27.16) |   |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Wells et al., 2014[19](#_ENREF_19) (continued) |   | G2 Pre-tx: 31.5 (10.32)G2 Post-tx: 15.3 (11.89)G2 3 month followup: 13.1 (7.4)Mean difference: 16.2 (Se = 3.93), p = 0.003, (95% CI, 7.31 to 25.09)G3 Pre-tx: 36.8 (16.22) G3 Post-tx: 34.3 (15.00)G3 3 month followup: NAMean differences, post-tx: 2.5 (SE = 1.86), (95% CI, -1.70 to 6.70)Treatment X time: F=10.33, p < 0.0005Hedge's g:G1 Pre-Post: 2.18G2 Pre-Post: 1.19G1 Pre-FU: 1.09G2 Pre-FU: 1.34ANCOVA group effect: F = 14.63, p < 0.0005G1 vs G3 Pre-Post: 20.88 (SE = 4), p < 0.0005, (95% CI, 10.64 to 31.11)G2 vs G3 Pre-Post: 15.5 (SE = 3.94), p = 0.002, (95% CI, 5.42 to 25.57)G1 vs G2 Pre-Post: 5.38 (3.88), p = ns, (95% CI, -15.30 to 4.54)ANCOVA group effects at followupG1 vs. G2: F = 0.04, p = 0.85 |   |   |   |

| Author, Year | Intervention Groups | Comorbid Medical Condition | QOL | Disability/Functional Impairment | Return to Work/Active Duty OR Ability to Work |
| --- | --- | --- | --- | --- | --- |
| Yeh et al., 2011[79](#_ENREF_79) | G1: Topiramate25 to 200mg/dayG2: Placebo | BDIMean(SD)G1 Pre-tx: 22.29 (9.47)G1 Post-tx 13.81 (10.29)G2 Pre-tx: 22.0 (11.80)G2 Post-tx:18.14 (14.77)Between Group Change, p=0.72 | NR | NR | NR |
| Zlotnick et al., 2009[56](#_ENREF_56) | G1: Seeking Safety;G2: Usual carePsychoeducational group and individual case management and drug counseling  | Addicition Severity IndexMean difference (95% CI)0.01 (-0.06 to -0.08) | NR | NR | NR |
| Zohar et al., 2002[72](#_ENREF_72) | G1: Sertraline50 to 200 mg/dayG2: Placebo | MADRSMean Change from Baseline (SD)G1: -9.17 (3.13)G2: -5.96 (3.33)NS | NR | NR | NR |

ANOVA = analysis of variance; ANCOVA = analysis of covariance; BAI = Beck Anxiety Inventory; BDI = Beck Depression Inventory; CES-D = Center for Epidemiologic Studies Depression Scale; CI = confidence interval; FU = Followup; GAF = Global Assessment of Functioning; GHQ-28 = General Health Questionnaire (28 item); HADS-A =Hospital Anxiety Scale; HADS-D = Hospital Depression Scale; HAM-A = Hamilton Rating Scale for Anxiety; HAM-D = Hamilton Rating Scale for Depression; MADRS = Montgomery–Åsberg Depression Rating Scale; NR= not reported; NS = not significant; PHQ = The Patient Health Questionnaire; Pre-tx = pretreatment; Post-tx = Posttreatment; PTSD= Post-Traumatic Stress Disorder; Q-LES-Q-SF = Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form; QOL = quality of life; RMANOVA, repeated measures analysis of variance; SD = standard deviation; SDS = Sheehan Disability Scale; SE = standard error; SF-36 = Short Form (36) Health Survey; SF-36V =Veterans Short Form 36 Questionnaire; STAI = State-Trait Anxiety Inventory; SUI = Substance Use Inventory.